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Abstract 
G-Protein coupled receptors (GPCRs) represent the largest superfamily 
of cell surface receptors in the human genome. They mediate the cellular 
responses to an enormous diversity of endogenous signaling molecules 
such as hormones and neurotransmitters, as well as environmental signals 
such as pheromones, smells, tastes and light. Because of the enormous 
diversity in transmitted signals, GPCR signaling is involved in nearly 
every physiological process, and deregulated signaling readily leads to 
pathologic conditions. Currently, about 25% of all drugs in clinical use 
exert their action by targeting GPCRs. 
Understanding the molecular mechanisms of ligand binding and signal 
transduction at the structural level of single atoms holds great promise for 
the detailed characterization of GPCR function and structure-based drug 
discovery. However, functional characterization and effective drug design 
of these receptors is strongly restricted by the limited availability of high-
resolution structural information. This limitation is mainly a consequence 
of the enormous experimental difficulties inherent to the process of 
atomic-resolution determination of GPCR structure. 
This thesis describes the development and application of powerful 
directed evolution methods aimed at improving the biophysical properties 
of GPCRs to make these receptors amenable to atomic-resolution 
structural studies. The initial studies have focused on engineering a 
water-soluble analog of the  !2 adrenergic receptor (ADRB2) by a 
complete redesign of its hydrophobic phospholipid-contacing surface. 
Computational methods were used to design a combinatorial gene library 
from which water-soluble ADRB2 analogs can be selected by modern in-
vitro selection technologies and further evolved towards the desired 
biophysical and functional properties. 
The more recent studies presented in this thesis describe the 
development of a powerful directed evolution method for producing well-
expressed and stable GPCRs in the inner membrane of the expression 
host Escherichia coli. The method is based on introducing random amino 
acid changes to a GPCR sequence and selecting improved receptor 
variants by fluorescence-activated cell sorting. The performance of the 
method was first critically assessed on the model protein neurotensin 
receptor NTR1 and then successfully applied to three additional human 
GPCRs – some of which were hardly expressed or quickly lost their 
native fold when solubilized in detergent micelles. For all four receptors, 
mutations could be evolved that showed strongly increased functional 
expression levels (up to 30-fold) and greater receptor stability. The 
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improvements are achieved by a combinatorial approach that does not 
require the input of rational design principles. 
In summary, by introducing the concepts of directed evolution to the 
field of integral membrane proteins, this work has produced powerful 
protein design strategies for GPCRs and a set of well-behaved GPCR 
proteins that are amenable to crystallographic studies. Existing 
roadblocks in structural and biophysical studies of these important 
receptors can now be removed by providing sufficient quantities of 
correctly folded and stable receptor protein. The ability to obtain atomic-
resolution structures may help to elucidate the molecular basis for 
activation, inactivation, or pathology associated with that receptor, and 
may also provide valuable templates for drug design. 
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Zusammenfassung 
G-protein gekoppelte Rezeptoren (GPCRs) stellen die grösste Protein-
Superfamilie im menschlichen Genom dar. Deren Aufgabe ist es, äussere 
Signale, z. B. von Hormonen oder Neurotransmittern aber auch 
Sinneswahrnehmungen wie Geruch oder Licht, ins Zellinnere 
weiterzuleiten und in der Zelle eine physiologische Antwort auszulösen. 
Aufgrund ihrer Fähigkeit eine Vielzahl äusserst unterschiedlicher Signale 
zu verarbeiten, hängen die meisten physiologischen Prozesse im 
menschlichen Körper von der Aktivität der GPCRs ab. Gerät eine 
bestimmte GPCR-abhängige Signalverarbeitung jedoch ausser Kontrolle, 
können leicht pathologische Prozesse ausgelöst werden. Dies macht 
GPCRs zu prominenten Kandidaten in der pharmazeutischen Industrie 
und erklärt auch weshalb jedes vierte Medikament auf dem Markt in die 
Aktivität GPCR-abhängiger Signalverarbeitung eingreift. 
Wäre man nun in der Lage, bestimmte funktionelle Aspekte G-protein 
gekoppelter Rezeptoren auf der strukturellen Ebene einzelner Atome 
genauer beschreiben zu können (z.B. die räumliche Konfiguration einer 
Bindesstelle für Liganden), ergäben sich daraus nicht nur wertvolle 
Erkenntnisse für die Grundlagenforschung sondern auch neue 
Möglichkeiten für die strukturgestützte Medikamentenentwicklung. 
Detaillierte strukturelle Einblicke sind heute jedoch nur sehr beschränkt 
möglich, weil trotz grosser Anstrengungen nur einige wenige 
hochaufgelöste Kristallstrukturen von GPCRs gemessen werden konnten. 
Diese Beschränkung besteht vor allem auf Grund der grossen 
experimentellen Schwierigkeiten bei der Röntgenstrukuranalyse von 
GPCRs. 
Die vorliegende Arbeit beschreibt die Entwicklung und Anwendung 
neuer Methoden auf dem Gebiet des Protein Engineering, die die 
biophysikalischen Eigenschaften von GPCRs verbessern und damit die 
Strukturanalyse dieser Proteine ermöglichen sollen. Der erste Teil dieser 
Doktorarbeit hatte zum Ziel wasserlösliche Analoga des !2-adrenergen 
Rezeptors zu konstruieren, indem der problematische wasserabweisende 
Anteil der Proteinoberfläche stark verringert wurde. Mittels 
computergestüzter Analysen wurde eine kombinatorische Genbibliothek 
des Rezeptors entworfen. Aus dieser sollten mit Hilfe von in-vitro 
Selektionsmethoden funktionale wasserlösliche Analoga des  !2-
adrenergen Rezeptors selektiert werden können. 
Der zentrale Teil dieser Doktorarbiet beinhaltet die neueren Studien 
zur Entwicklung einer effizienten Selektionsmethode zur Herstellung 
hoch exprimierender und stabiler GPCRs im Expressionsorganismus 
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Escherichia coli. In dieser Methode wird die Aminosäuresequenz eines 
experimentell schwierig zu handhabenden GPCR zuerst nach dem 
Zufallsprinzip mutiert. Mit Hilfe eines Durchflusszytometers können 
dann diejenigen Mutanten isoliert werden, die eine erhöhte funktionale 
Proteinexpression aufweisen. Die Effizienz der Methode wurde zuerst am 
Modellprotein Neurotensinrezeptor NTR1 gezeigt und danach erfolgreich 
auf drei weitere humane GPCRs angewendet. Für alle vier 
Ausgangsmoleküle konnten neue Varianten evolviert werden, die eine 
stark verbesserte funktionale Proteinexpression (bis zu 30 mal höher als 
das Ausgangsmolekül) und eine höhere Proteinstabilität aufwiesen. 
Zusammenfassend resultierten aus dieser Arbeit neue effiziente 
Strategien für das Protein Engineering von G-protein gekoppelten 
Rezeptoren. Weil die evolvierten Proteine sehr stabil sind und in 
ausreichender Menge hergestellt werden können, entfallen nun einige der 
grössten Hürden im Prozess der Röntgenstrukturanalyse von GPCRs. Die 
Entdeckung neuer Kristallstrukturen von GPCRs würde dadurch 
vereinfacht und könnte dazu beitragen, die molekularen Mechanismen 
der Rezerptor-Aktivierung, der Rezeptor-Inaktivierung oder 
pathologischer Zustände besser zu verstehen. Auch die Entwicklung 
verbesserter Medikamente mit Hilfe strukturbasierender Methoden würde 
durch detaillierte Rezeptorstrukturen vorangetrieben. 
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Chapter 1 2 
1.1 Structure and function of G-protein 
coupled receptors 
G-Protein coupled receptors (GPCRs) are cell surface receptors that 
mediate the cellular responses to an enormous diversity of endogenous 
signaling molecules such as hormones and neurotransmitters, as well as 
environmental signals such as pheromones, smells, tastes and light 
(Fig. 1.1). The list of ligands detected by members of the GPCR family 
range from peptides and protein hormones (e.g. angiotensin, bradykinin, 
neurotensin, substance P), biogenic amines (e.g. adrenaline, dopamine, 
histamine, serotonin) and lipids and eicosanoids (e.g. cannabinoids, 
leukotrienes, prostaglandines, thromboxanes), nucleotides and 
nucleosides (e.g. adenosine, ADP, ATP, UTP) and a wide variety of other 
molecules down to Ca2+ ions and photons (light). Binding constants are 
available for several thousand ligand-receptor combinations1,2. 
 
 
Figure 1.1: Schematic representation of the signaling mechanism of G-protein 
coupled receptors. 
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Despite the chemical and functional diversity of the signaling 
molecules recognized by the GPCRs, all of the G-protein coupled 
receptors are related on the sequence level, have the same membrane 
topology and are predicted to have a similar three-dimensional structure. 
They consist of a single polypeptide chain that threads back and forth 
across the phospholipid bilayer of the cell membrane seven times, with 
the N-terminus located on the exterior side of the plasma membrane and 
the C-terminus on the cytoplasmic side. From this conserved membrane 
topology stems their alternative name of “seven transmembrane domain 
receptors” (7TM). 
The G-protein coupled receptors constitute one of the largest protein 
superfamilies. The Caenorhabditis elegans genome encodes ~1100 
GPCRs (5% of all open reading frames), while in vertebrates the GPCR 
superfamily contains 1000-2000 members (>1% of the open reading 
frames)3. In the human genome approximately 800 GPCRs have been 
found, of which half are olfactory receptors, while half are thought to 
represent receptors for endogenous ligands3,4. The latter group can be 
subdivided into five sequence families according to the GRAFS 
classification system, which is strictly based on phylogenetic criteria5. 
The largest of theses families – the rhodopsin family – contains about 270 
different receptors. An alternative name commonly seen for this family is 
Class A GPCRs6,7. Despite the very low sequence identity found among 
the members of the rhodopsin family, there are several sequence 
characteristics that indicate the common evolutionary decent of this 
family. These characteristics include the D(E)-R-Y(F) motif in TM3, the 
NSxxNPxxY motif in TM7, and several additional highly conserved 
amino acids found in each transmembrane helix of the 7TM fold. 
All GPCRs share a common signaling mechanism, utilizing 
heterotrimeric G-proteins8 (guanine nucleotide binding proteins) as 
second messengers (Fig. 1.1). The signaling mechanism of these 
heterotrimeric G-proteins depends on the dissociation of their G! subunit 
from the G"# subunit complex, stimulated by the exchange of guanine 
nucleotide diphosphate for guanine nucleotide triphosphate on the G! 
subunit. The complex of the G"# subunit can then modulate the activity 
of various effector proteins such as membrane channels and enzymes, e.g. 
adenylyl cyclases, phosphodiesterases, phospholipases, Ca2+ and K+-
channels. 
Over the last years it has become apparent that GPCR mediated 
signaling goes beyond the classical mechanisms involving G-proteins. 
Numerous proteins have been found to interact with GPCRs, which may 
help to explain the remarkable diversity of cellular responses mediated by 
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these receptors. The effects of these proteins may range from small 
refinements of a transmitted signal to large shifts in signal trafficking. A 
prominent example are the "-arrestins. They have been found to be 
involved in several regulatory processes, such as receptor desensitizing 
and internalization. But they also serve as scaffolding proteins to 
facilitate the formation of G-protein independent signaling complexes9. 
There are many other examples of GPCR-activated signaling cascades 
that do not depend on G-protein recruitment10. 
Because of the wide variety of transmitted signals, GPCRs are 
involved in nearly every physiological process and deregulated signaling 
readily leads to pathologic conditions. This makes these receptors prime 
targets for drug development. Presently, about 25% of all known drugs in 
clinical use target GPCRs11. But these drugs hit merely 10% 
(corresponding to about 30 different receptors) of the pharmacologically 
relevant (non-olfactory) GPCRs. The remaining majority of non-olfactory 
GPCRs are considered potential high-value drug targets, and exploring 
their therapeutic potential remains a major challenge in academic and 
industrial GPCR research. 
Understanding the molecular mechanisms of ligand binding and signal 
transduction at the structural level of single atoms holds great promise for 
the detailed characterization of GPCR function and protein-based drug 
discovery. The molecular structure of GPCRs specifies their chemical 
interaction with diffusible ligands and intracellular effector proteins and 
ultimately defines their role in physiology and pathology. However, 
functional characterization and effective drug design of these receptors is 
strongly restricted by the limited availability of high-resolution structural 
information. This limitation is mainly a consequence of the enormous 
experimental difficulties inherent to the process of atomic-resolution 
determination of GPCR structure. 
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1.2 Experimental difficulties in biochemistry 
and structural biology of GPCRs 
The structural and functional study of integral membrane proteins is 
considerably hampered by the hydrophobic nature of these proteins. 
Problems commonly appreciated include low expression levels, toxicity 
to cells forced to overexpress these molecules, limited stability and 
aggregation in detergent-solubilized form, and the inability to refold them 
from solubilized non-native aggregates in vitro. A protein can only be 
crystallized and its atomic-resolution structure solved if it can be 
produced in sufficient amounts in soluble form and if it retains its native 
structure upon solubilization.  
Because of the experimental difficulties, only about 210 unique 
structures of membrane proteins have been solved so far12, as compared 
to ten thousands of structures of soluble globular proteins. Many of these 
represent proteins that are highly expressed in their natural source tissues 
or organelles, such as the visual cone pigment rhodopsin, the 
photosynthetic reaction center, photosystems and components of the 
respiratory chain. Other membrane proteins show a high intrinsic 
biophysical stability, which favors their functional solubilization in 
detergent micelles. Examples include "-barrel porins and !-helical ion 
channels. Yet others, such as the monotopic membrane proteins or  !-
helical transporters, contain relatively large intracellular and extracellular 
domains, minimizing the fraction of hydrophobic surface that needs to be 
masked with detergents to solubilize the protein. However, most 
membrane proteins, such as the members of the GPCR superfamily, are 
very difficult to express, rapidly unfold in detergent micelles and lack 
large hydrophilic surfaces for forming crystal contacts. 
While GPCRs can be recombinantly expressed in eukaryotic cells at 
the low expression levels needed for binding studies and for the 
investigation of receptor signaling functions, so far most attempts to 
produce GPCRs in soluble form in amounts and quality suitable for 
crystallization have failed. A breakthrough in high-resolution X-ray 
crystallography was the structure determination of the bovine visual cone 
pigment rhodopsin at 2.8 Å in the year 200013. These structural studies 
were made possible because the protein can be functionally purified in 
large amounts from bovine retinal tissue and because it can be maintained 
in its relatively stable non-signaling conformation. In recent years four 
more GPCR structures could be solved: the squid rhodopsin14, the human 
"2 adrenergic receptor15,16, the turkey "1 adrenergic receptor17, and the 
human adenosine receptor A2A18. These proteins, with the exception of 
squid rhodopsin, had to be overexpressed in a heterologous expression 
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system, the baculovirus system. A handful of additional GPCRs can be 
recombinantly expressed and purified in functional form at levels 
necessary for structural studies. These include the human histamine 
receptor H1 expressed in the baculovirus system19, and the rat neurotensin 
receptor NTR1 and the human cannabinoid receptor CB2 both expressed 
in Escherichia coli20,21. For most GPCRs, however, finding satisfactory 
overexpression conditions remains very challenging. 
Establishing a strong overexpression system represents only the first 
experimental obstacle towards the production of large amounts of a 
GPCR protein suitable for structural studies. Unlike soluble globular 
proteins, integral membrane proteins absolutely require the help of 
amphipathic detergent molecules to extract them from their natural 
physical environment – the phospholipid membrane – and to transfer 
them into a soluble state established by detergent micelles. This process 
is problematic from a thermodynamic point of view because the physical 
environment provided by the detergent micelle is very different from the 
phospholipid membrane. Protein solubilization by detergents therefore 
frequently leads to protein unfolding, aggregation, and loss of function.  
For GPCRs the solubilization process turns out to be particularly 
destructive because of their intrinsic biophysical instability. GPCRs 
naturally exist as structurally flexible molecules to exert their function in 
transducing extracellular signals across the phospholipid bilayer22. The 
observation that GPCRs can activate G-proteins even in the absence of an 
activating agonist ligand, a phenomenon called basal activity, implies that 
the receptors can continuously adapt different thermodynamic receptor 
conformations. This structural and thermodynamic heterogeneity is most 
likely responsible for the rapid receptor unfolding observed upon receptor 
solubilization with detergents. 
Crystallographic studies remain very challenging even if a protein can 
be overexpressed in large amounts and solubilized in its active form. For 
integral membrane proteins, crystal contacts are normally formed by 
amino acids of the polar surface area of the protein and not by the 
hydrophobic surface, which is masked by detergent molecules. In many 
cases however, the polar surface area represents only a minor fraction of 
the total surface area of the protein-detergent particle. Therefore, the 
likelihood of forming stable crystal contacts is strongly limited and 
obtaining diffraction-quality crystals remains very difficult. There are 
some tricks used to overcome the difficulty offered by the crystallization 
of proteins that have much of their molecular surface masked by 
detergents. Among them is the increase of the hydrophilic surface by co-
crystallizing the membrane protein as a complex with an antibody 
fragment15,23-25 or with a designed ankyrin repeat protein26 or by 
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expressing the protein as a fusion to a highly soluble and well-folding 
domain16,18. 
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1.3 Current strategies for overcoming the 
difficulties in the production of integral 
membrane proteins 
For improving the process of producing a membrane protein at sufficient 
amounts and quality for crystallization, an ever-growing number of 
biochemical techniques are being developed and implemented. The high 
pace of the methodological development most probably reflects the 
observation that experimental parameters need to be optimized 
individually for any given target protein.  
Currently there are three different strategies for increasing the chances 
of producing a well-expressed, soluble, and active membrane protein. 
The first strategy, which is the most intuitive and most widely used one, 
relies on the extensive screening of a large number of experimental 
conditions for expression and solubilization of a given construct. 
Typically, these conditions have to be optimized for any given target 
protein. A second strategy relies on the screening of protein homologs in 
order to identify a candidate that shows biophysically favorable 
properties. The homologs are usually screened in the context of a few 
globally optimized conditions for expression and solubilization. A third 
strategy involves the techniques of protein engineering to improve the 
biophysical properties of a target protein itself that otherwise fails to be 
overexpressed and solubilized. While the first strategy aims at the 
optimization of extrinsic experimental parameters, the latter two 
strategies focus on the intrinsic biophysical properties of the target 
protein itself. In the following the three strategies are discussed in more 
detail. 
1.3.1 The classical strategy: Screening of extrinsic 
experimental parameters 
The most common approach for finding suitable overexpression 
conditions for a given membrane protein is the systematic examination of 
a variety of different expression parameters. These parameters typically 
include the screening of expression hosts (prokaryotes and eukaryotes), 
promoters, N-terminal and C-terminal fusion adducts, expression media, 
and expression temperature. For the functional expression of GPCRs in 
the versatile host E. coli a combination of the following expression 
parameters has been found beneficial for some receptors: A genetic 
fusion of maltose binding protein to the receptor N-terminus and a 
thioredoxin A fusion to its C-terminus, combined with a low expression 
temperature (e.g. 20 °C). However, despite the fact that large resources 
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are invested in the process of optimizing expression parameters, many 
membrane proteins, especially those of eukaryotic origin, fail to be 
overexpressed in functional form.  
In a recent study on the expression of GPCRs in bacteria it has been 
shown that functional expression can be improved by genetic engineering 
of the expression host. Co-expression of additional copies of the 
membrane-bound AAA+ protease FtsH, enabled the efficient production 
of the human cannabinoid receptor CB1 in E. coli27. A similar effect was 
obtained by inactivating the chaperone DnaJ by a Tn5 insertion28. 
Genetically engineered expression hosts may therefore enable the 
production of membrane-integrated human GPCRs that are otherwise 
difficult to express, but the general applicability of this strategy remains 
to be demonstrated. 
Cell-free production of functional GPCRs by the help of so-called 
nanodisks has been shown to be possible for several receptors29-31. If this 
technology proves to be generally applicable to integral membrane 
proteins, it may represent a very interesting alternative to cell-based 
expression systems. 
If sufficient amounts of a membrane protein can be expressed, the next 
step that has to be optimized before initiating crystallization trials is to 
purify the protein. For the purification process the protein has to be 
handled in solution. Therefore, solubilization conditions have to be 
established that allow the protein to be efficiently extracted from the 
phospholipid bilayer and maintained in a functional form in solution. The 
choice of a detergent that satisfies such conditions cannot be made 
rationally, because the molecular interactions between protein and 
detergent are not well understood. Rather, finding an appropriate 
detergent for any given protein relies on the screening of many different 
detergents32. As for the screening of expression conditions, detergent 
screens are very laborious and many proteins fail to be solubilized in 
functional form. 
Interestingly, if the protein is intended for crystallization, the choice of 
the detergent seems to be strongly limited. A systematic analysis of the 
crystallization conditions of solved structures of !-helical membrane 
proteins shows that only a small group of detergents conform to the 
formation of diffraction quality crystals33. In 90% of the successful 
crystallizations the detergents were alkyl maltopyranosides, alkyl 
glucopyranosides, or polyoxyethylene glycols. This implies that if a 
membrane protein fails to be functionally solubilized in one of these 
detergents, the protein will be very difficult to crystallize. 
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1.3.2 The genomic strategy: Screening of homologs 
If the extensive screening of extrinsic experimental parameters fails, a 
second strategy referred to as homolog screen can be employed for 
increasing the chances of obtaining a well expressed and properly 
behaved membrane protein. With the advent of the genomics era the data 
of hundreds of fully sequenced genomes have become available, which 
allows the rapid cloning of many homologous sequences of a protein of 
interest. A set of homologs can then be screened in parallel to identify the 
most promising candidates for crystallization trials. When homologs are 
screened, other experimental parameters are usually kept rather constant. 
Therefore, the homolog screen usually involves a few globally optimized 
expression conditions and a small set of detergents, which are likely to 
promote crystal contact formation. The crystal structures of many 
membrane proteins, mostly of prokaryotic origin, could be solved by this 
strategy. However, if the research goal is to solve the structure of a 
particular membrane protein – for example a particular human GPCR – 
screening of homologs is not a suitable option. For proteins such as 
GPCRs, there are no bacterial homologs. 
In order to accelerate screening of large sets of homologs (or a large 
variety of expression conditions for that matter), new technologies are 
continuously being developed. For example, fusing GFP to a membrane 
protein has been shown to be a good indicator for productive 
overexpression in E. coli and this system has been successfully 
implemented in many screens34,35. GFP fluorescence can also be used for 
quality control of membrane protein folding36. 
1.3.3 The protein engineering strategy: Improving the 
biophysical properties of the protein 
The third strategy for improving the production of a membrane protein is 
based on the assumption that the biophysical properties of the protein 
itself can be improved by modifying the underlying amino acid sequence. 
In the research field of soluble globular proteins, biophysical properties, 
such as protein expression, stability, or solubility, are routinely improved 
by a strategy commonly referred to as protein engineering. However, 
most of the highly efficient protein engineering methods for soluble 
proteins cannot be applied directly to integral membrane proteins, due to 
the hydrophobic nature of these proteins. Developing protein engineering 
methods for integral membrane proteins represents the basis of the 
present doctoral thesis. 
In the field of protein engineering, there are basically two ways of 
improving the biophysical properties of a given target protein. The first 
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relies on modifying the amino acid sequence of a protein by rational 
design. This approach usually requires a detailed structural or 
mechanistic description of the protein that is to be engineered. For many 
biochemical problems, however, either this information is not available, 
or, if it is available, the modifications required to rationally design a 
desired phenotype are too complex to be predicted. The second approach 
relies on engineering a protein by “irrational” design. This strategy is 
more powerful than rational design because it explores the evolutionary 
principles observed in nature, namely random mutagenesis and selection, 
to generate a desired molecular property. This concept is known as 
directed evolution and the underlying methods are called display methods 
or selection methods. The strength of directed evolution lies in the fact 
that a desired molecular property can be obtained based on very low input 
information. Moreover, because the methods employed by directed 
evolution explore the evolutionary potential of a protein in a 
combinatorial fashion, it is possible to evolve biophysical properties that 
are based on complex molecular interactions, such as the ones defining 
protein expression or thermodynamic stability. 
The procedure for engineering the properties of a given protein 
involves two experimental steps. First, the introduction of modifications 
to the genetic sequence coding for a protein of interest, such as point 
mutations, insertions, or deletions, generates a set of diversified protein 
variants. As mentioned before, genetic diversity can be generated either 
by introducing specific mutations in a rational way or by mutagenizing 
the gene randomly. Second, the mutant protein variants are analyzed in 
the context of a functional assay in order to identify candidates showing 
the desired molecular property. For the second step, a distinction can be 
made between two experimental approaches for identifying improved 
candidates. If the number of mutant protein variants under investigation is 
relatively small – in the range of hundreds, as is often the case in rational 
design experiments – the different variants can be analyzed one-by-one 
by a screen. However, if a larger sequence space needs to be analyzed, 
for example in an attempt to evolve a particular protein variant based on a 
pool of millions of randomly mutagenized proteins, it is not possible to 
screen each variant individually. In this case the methods of directed 
evolution, which are based on genetic selection rather than screening, are 
more appropriate. 
Although the principles of protein engineering have been applied to 
membrane proteins for more than 15 years37,38, there have been far less 
studies on membrane proteins than on soluble proteins. Since appropriate 
methods for the directed evolution of membrane proteins were not 
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available until recently, most of the reported studies were based on 
screening small sets of mutants.  
In 1999, Bowie and coworkers found that the thermal stability of the 
integral membrane protein diacylglycerol kinase could be increased by 
engineering cysteine-substituted variants39. Interestingly, two out of the 
20 mutants they analyzed showed a stabilizing effect in detergent 
solution. In a subsequent study they screened a larger set of mutants and 
were able to further increase the thermal stability40. They concluded that 
stability-enhancing mutations appear to be relatively common in 
membrane proteins41. This observation inspired other research groups, 
including our own, to explore the potential of protein engineering for 
improving the biophysical properties of integral membrane proteins. 
Nordlund and coworkers for example have developed a dot-blot based 
method for screening relatively large sets of random mutants (in the range 
of thousands) for higher protein expression. Their approach, however, 
fails to distinguish between correctly folded and incorrectly folded 
protein. Tate and coworkers have applied a simple alanine scan to 
identify GPCR mutants showing increased thermal stability in detergent 
solution. This strategy has worked for a couple of GPCRs42 and made 
possible the determination of the crystal structure of the  "1 adrenergic 
receptor17. Nevertheless, the strategy suffers form a basic limitation. Its 
application is limited to GPCRs that show a relatively high wild-type 
expression, which excludes the majority of GPCRs that fail to be 
expressed above a certain threshold level. Moreover, because the strategy 
is limited to the screening of individual point mutants it fails to explore 
the full evolutionary potential of a target protein.  
Despite their limitations, the emerging protein engineering methods 
clearly open a new dimension to the field of membrane protein 
biochemistry and crystallography. The objective of the present thesis is 
the development and application of protein engineering methods that 
enable the improvement of the biophysical properties of integral 
membrane proteins, particularly of GPCRs. The main part of the studies 
is centered on the development of directed evolution methods for 
engineering highly expressed and stable GPCR variants. 
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1.4 Development of new methods for the 
directed evolution of GPCRs for 
expression and stability 
The first study conducted during my doctoral thesis addressed the 
possibility of solving the experimental problems generally observed with 
GPCRs by a protein engineering approach that is focused on the 
biophysical properties of the protein surface. The idea was to convert the 
hydrophobic surface of a GPCR, which is naturally immersed in the 
phospholipid bilayer and causes most of the experimental trouble, into a 
hydrophilic surface. This would alleviate the problems caused by the 
hydrophobic nature of the protein and would allow to handle the 
resurfaced GPCR as if it was a soluble globular protein. The 
modifications on the protein surface should preserve the 7TM fold and 
the ligand binding competence of the GPCR. To this end, a strategy was 
developed for replacing the hydrophobic side chains on the protein 
surface, which normally have to be protected by detergent molecules, by 
hydrophilic side chains. We chose the "2 adrenergic receptor as a model 
system. 
The problem of engineering a water-soluble   "2 adrenergic receptor is 
far too complex to be solved by a rational design approach. We therefore 
decided to develop a combinatorial strategy that employs the principles of 
directed evolution, namely mutagenesis and selection. In Chapter 2 of 
this thesis I present the theoretical concept and the synthesis on the DNA 
level of a semi-rational gene library that is designed for the selection of 
water-soluble "2 adrenergic receptor variants. The genetic selection on 
this library, however, has not yet been carried out. 
The complete resurfacing of a GPCR presented in Chapter 2, 
represents a very radical way of engineering a membrane protein and the 
risk of evolving a protein variant that shows impaired function is 
relatively high. A less radical approach for improving the biophysical 
properties of a GPCR is presented in Chapter 3 of this thesis. It deals 
with the engineering of GPCRs by swapping specific domains, such as 
transmembrane helices, between homologous proteins. We produced 
receptor chimeras between the µ-opioid receptor (MOR), which behaved 
very poorly upon solubilization from membranes and the $-opioid 
receptor, which proved somewhat more robust. Replacing a short stretch 
of sequence in MOR by the corresponding sequence from the KOR 
improved the behavior of the MOR to the level of that of the KOR while 
preserving the ligand specificity and affinity of the µ-opioid receptor. 
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The third and the fourth study (Chapters 4 and 5) in this thesis 
describe how the functional expression level and the biophysical stability 
of GPCRs can be strongly improved by introducing small changes to the 
amino acid sequence. These studies describe the development and critical 
assessment of a general method for the directed evolution of GPCRs. It 
represents the first report of applying the principles of directed evolution 
to the field of integral membrane proteins. The remainder of this 
introductory chapter is dedicated to a short overview on the application of 
directed evolution methods to the research field of integral membrane 
proteins. It leads to the introduction of the studies presented in the 
Chapters 4 and 5. 
In the research field of soluble proteins, there exist a variety of directed 
evolution methods that exploit the natural principle of random 
mutagenesis and selection to isolate a desired mutant protein from a large 
pool of randomly mutagenized proteins. Each method is specified by a 
different mode of establishing a physical linkage between a genotype and 
its phenotype. As it is the case for living organisms, this physical linkage 
is absolutely necessary for the progression of an evolutionary cycle 
because the desired molecular property is selected on the protein level 
(phenotype) while the corresponding genetic information is encoded in 
the DNA (genotype). From a technical point of view, the identity of a 
particular selected protein is much easier to be revealed from its DNA 
sequence than from its amino acid sequence. 
The different display methods for soluble proteins can be subdivided 
into two groups based on the mode by which the genotype-phenotype 
linkage is established. The in-vivo display methods make use of a living 
cell to establish the genotype-phenotype linkage and the protein is mostly 
displayed on the surface of the host cell. The most widely used host cell 
types for cell-surface display are bacteria and yeasts, but more complex 
cell types have been used as well. The in-vitro display methods, on the 
other hand, employ a cell-free and more direct mode for linking the 
protein to its corresponding DNA or mRNA. In ribosome display the 
protein is translated in vitro and the ribosome itself is used to link the 
translated protein with its mRNA43-45. In phage display the protein is 
encoded on the DNA encapsulated inside a phage particle and the protein 
is displayed on the phage surface46,47. In mRNA display the protein is 
translated in vitro and tethered directly to its mRNA48-51. In in-vitro 
compartmentalization both the protein and its mRNA are constrained 
within aqueous droplets (compartments), which are formed in a water-in-
oil emulsion45,52,53. 
The cell-free in-vitro display methods developed for soluble proteins 
cannot be directly applied to membrane proteins, because the folding 
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mechanism of integral membrane proteins is not compatible with these 
methods. In most cases, integral membrane proteins fail to fold correctly 
under in-vitro conditions, which do not provide the physico-chemical 
environment of a lipid bilayer and the translocation machinery. However, 
the concepts of in-vivo display methods, such as cell-surface display, 
could potentially be adapted for the directed evolution of integral 
membrane proteins. Chapter 4 of the thesis describes the development of 
an efficient in-vivo display method for the directed evolution of GPCRs 
in Escherichia coli. It aims at improving functional expression, 
biophysical stability, and ligand selectivity. The performance of the 
method was critically assessed using the model protein neurotensin 
receptor NTR1. In a follow-up study presented in Chapter 5, I further 
validated the method by applying it successfully to three additional 
human GPCRs, including a GPCR that can hardly be expressed in 
functional form in E. coli. 
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2.1 Abstract 
Despite enormous efforts made in generating atomic-resolution structures 
of G-protein coupled receptors, there are only five structures solved so 
far. Here we propose a radically new strategy for overcoming the 
experimental problems inherent to the study of integral membrane 
proteins by engineering water-soluble analogs of GPCRs suitable for X-
ray crystallography. We use rational design for the generation of gene 
libraries from which improved molecules can be selected and further 
evolved towards the desired biophysical and functional properties. 
Starting from a homology model of the  !2 adrenergic receptor structure, 
computational methods are used to identify amino acid positions suitable 
for randomization while limiting the combinatorial complexity of the 
library to a level that can be handled by modern in-vitro selection 
technologies. Ribosome display will allow the selection and further 
improvement of receptor variants capable of achieving their native fold 
and ligand binding competence in an aqueous environment. 
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2.2 Introduction 
Membrane and water-soluble proteins both show similarly organized 
protein cores, predominantly composed of closely packed hydrophobic 
amino acids. The main difference between soluble proteins and integral 
membrane proteins lies in the fact that the molecular surface of water-
soluble proteins is predominantly composed of hydrophilic amino acids, 
while in membrane proteins, those parts of the molecular surface that are 
normally immersed in the phospholipid bilayer are predominantly 
hydrophobic. In water-soluble globular proteins, the hydropathic contrast 
between the hydrophobic protein interior and the hydrophilic surface 
plays a major role in the folding process. Increasing the proportion of 
solvent-exposed hydrophobic amino acids in such proteins can 
significantly lower their folding efficiency. In contrast, membrane 
proteins utilize the secretion/membrane insertion machinery of the cell to 
insert the protein into the membrane, where the hydrophobic surface 
residues are surrounded and chaperoned by lipids.  
Here we propose to replace the phospholipid-exposed hydrophobic 
residues within the transmembrane (TM) domains of the GPCRs with 
more hydrophilic residues to engineer water-soluble variants of GPCRs 
capable of folding in aqueous solutions. The proof-of-concept for the idea 
that membrane proteins can be resurfaced and converted into soluble 
globular proteins while maintaining a similarly packed protein core has 
been presented1-4: Frank and coworkers were the first to design resurfaced 
mutants of the single transmembrane helix protein phospholamban. These 
variants showed increased solubility over the wild-type protein and 
associated into a native-like pentameric coiled-coil structure. The crystal 
structure of a water-soluble phospholamban analog could be solved5. 
More recently, a computational design procedure was applied to engineer 
water-soluble variants of the prokaryotic potassium channel KcsA4. The 
resulting analogs were expressed with high yields in E. coli and 
mimicked some of the functional properties of the wild-type channel in 
aqueous solution, such as oligomerization state and binding of specific 
channel- blocking agents.  However, efforts to engineer water-soluble 
resurfaced mutants of the larger protein bacteriorhodopsin resulted in 
proteins that were unable to adopt the wild-type fold and as a 
consequence showed very low solubility in water6. The positive results of 
successful solubilization strategies in other groups1-5 inspired us to 
develop new methods for redesigning the transmembrane domain of 
GPCRs. This study aims to produce GPCR analogs, which are soluble 
and stable in water and can be expressed in high quantities to enable 
atomic-resolution biophysical studies. In this chapter I present the 
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theoretical concept and experimental synthesis of a semi-rational 
combinatorial gene library that is designed for the selection of water-
soluble analogs of the !2 adrenergic receptor (ADRB2).  
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2.3 Results and discussion 
2.3.1 Identifying phospholipid-exposed amino acids for 
randomization 
The problem of engineering a water-soluble !2 adrenergic receptor analog 
is far too complex to be solved by a rational design approach6. We 
therefore decided to develop a combinatorial strategy that employs the 
concept of directed evolution involving the mutagenesis of the 
!2 adrenergic receptor gene (ADRB2) and the isolation of water-soluble 
receptor analogs by in-vitro selection techniques such as ribosome 
display. The central idea of our approach is the computational design of a 
combinatorial gene library that contains receptor variants that fold into 
the 7TM fold in aqueous solution. These water-soluble analogs can then 
be isolated from the library via ribosome display by selecting for their 
ability to bind specific ADRB2 ligands, such as the antagonist alprenolol. 
In this chapter I describe the conceptual design and the synthesis of the 
gene library. The selection by ribosome display has not been carried out 
yet. 
In order to convert the hydrophobic surface of ADRB2 into a 
hydrophilic one, we first identified the highly surface-exposed amino acid 
positions that normally are immersed in the phospholipid bilayer. These 
positions would then be targeted for randomization in the gene library. To 
identify these positions we followed two lines of evidence. First, we 
constructed and analyzed a structural homology model for ADRB2. 
Second, we analyzed multiple sequence alignments of the adrenergic 
receptor family to identify highly variable – and thus presumably solvent-
exposed – amino acid positions. 
When we started this project in 2004, there was no high-resolution 
crystal structure available for the !2 adrenergic receptor, which made it 
difficult to identify the appropriate positions for randomization. We 
therefore constructed a homology model of the receptor based on the 
crystal structure of rhodopsin (PDB code 1f88), which was the only 
atomic-resolution structure of a GPCR available at that time7. This 
structure represents the non-signaling state of rhodopsin. Because we 
were mainly interested in the spacial orientation of the surface-exposed, 
lipid-contacting residues, rather than a detailed model of the entire 
receptor structure, we limited the homology model to the region of the 
seven TM helices.  
ADRB2 and rhodopsin both belong to the rhodopsin-like family of 
GPCRs. Although they share very low sequence identity (about 20% in 
the 7TM region), they do share some highly conserved sequence 
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characteristics (GPCR signature motifs) that are found in each of the 
seven TM helices. The homology model building started with the 
pairwise sequence alignment of human ADRB2 and bovine rhodopsin 
(Fig. 2.1a). The conserved signature motifs served as anchoring points 
for aligning the seven TM helices correctly. 
The initial structural model of ADRB2 was built by assigning the 
backbone coordinates for each aligned amino acid. The helix ends of 
ADRB2 were defined based on the rhodopsin structure. The ADRB2 side 
chains were then assigned to the backbone. This initial model is a simple 
duplication of the rhodopsin backbone carrying the ADRB2 side chains. 
The model was then refined. The spacial orientations of all side chains 
in the model were optimized by sampling a backbone dependent rotamer 
library. The orientations of residues comprising the GPCR signature 
motifs were kept as in the rhodopsin structure. All other side chains were 
optimized to remove steric clashes, and saturate hydrogen-bonding 
contacts. After optimizing the orientations of all side chains, strong steric 
clashes remained near the extracellular end of TM2 and along the 
interface between TM3 and TM4. These clashes could be removed by 
minor adjustments of the helix orientations of TM2 and TM4. TM2 was 
straightened up by moving the extracellular part of the helix away from 
the protein core. The helix kink in TM2 served as a hinge for this 
movement. Increasing the distance between TM3 and TM4 eliminated the 
steric clash between these two helices. To this end, the entire TM4, which 
is highly exposed to phospholipids, was moved away from TM3. The 
strong helical distortions (kinks induced by "- and 310 helical elements) 
observed in the template structure of rhodopsin were also incorporated 
into the homology model. The superposition of the final ADRB2 model 
on the ADRB2 crystal structure solved in 20078 (PDB code 2rh1) is 
illustrated in Figure 2.1b. The superposition shows a low RMSD value of 
1.1 Å between the C# atoms of the model and the ADRB2 crystal 
structure. 
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Figure 2.1: Homology modeling of the human ADRB2. (a) Pairwise sequence 
alignment of the seven TM helices of bovine rhodopsin and ADRB2 (TM1 
through TM7 from top to bottom). The signature residue that is most conserved 
in each TM among the rhodopsin family of GPCRs is indicated (*). (b) 
Superposition of the C# backbone coordinates of the ADRB2 homology model 
(orange ribbon) and the ADRB2 crystal structure (green ribbon, PDB code 
2rh1). (c, d) The 54 randomized amino acid positions placed on the ADRB2 
crystal structure as red C#-C! vectors. 
 
The quality of the refined homology model was verified by its 
consistency with experimental data. We were most interested to verify 
that the seven helices were oriented correctly to each other, i.e. that the 
phospholipid-exposed faces of each helix were indeed positioned on the 
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receptor surface. To this end, we reanalyzed data from an earlier study on 
the dopamine receptor D2, a close homolog of ADRB2, in the context our 
homology model. In this study, Javitch and coworkers9 had used the 
substituted-cysteine accessibility method (SCAM) for mapping the 
surface of the ligand-binding crevice in the D2 receptor. They mutated 
every residue of the seven TM helices to Cys, one at a time, and probed 
its accessibility to a charged sulfhydryl reagent. Water-accessible Cys 
residues in the ligand-binding crevice are expected to be vastly more 
reactive to the reagent than Cys facing lipid or facing the tightly packed 
protein core. By mapping their data on our homology model of ADRB2 
we found that the orientations of all seven helices were in good 
agreement with the experimentally found helix orientations in the 
D2 receptor. The homology model ADRB2 thus allowed identifying the 
most phospholipid-exposed amino acid positions on the surface of each 
of the seven TM helices. 
In addition to the structural information obtained from the homology 
model, we investigated a second line of evidence to identify appropriate 
amino acid positions for randomization. We constructed a multiple 
sequence alignment of nearly hundred !2 adrenergic receptor homologs 
from different species retrieved from NCBI’s GenBank and analyzed the 
amino acid variability for each aligned position. We supposed that 
phospholipid-exposed amino acid positions would be less conserved than 
positions facing the protein core. The positions showing the highest 
variability were mostly populated by the hydrophobic amino acids Ala, 
Gly, Ile, Leu, Val or Phe. In agreement with the structural analysis of the 
homology model, we found that the variable positions mostly overlapped 
with the phospholipid-exposed positions of the ADRB2 model (Fig. 2.2). 
Based on the analysis of the homology model and of the sequence 
variability data, we identified 54 amino acid positions that we assumed 
were highly phospholipid-exposed, and we decided to randomize those 
positions in the gene library of ADRB2. The 54 randomized positions 
correspond to 28% of the all amino acids in the seven TM helices and 
12% of the full-length ADRB2 receptor. When the crystal structure of the 
human !2 adrenergic receptor was published in 20078,10 we mapped the 
54 positions on this structure and found that all of them were indeed 
surface exposed as illustrated in Figures 2.1c and 2.1d. 
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Figure 2.2: Correlation between sequence variability of 95 aligned ADRB2 
homologs of different species (bars) and solvent accessible surface area in the 
ADRB2 homology model (!, SASA) for every residue in the seven TM helices. 
These data, along with visual inspection of the ADRB2 homology model, were 
used to define the 54 phospholipid-exposed amino acid positions for 
randomization (blue bars). The sequence variability at a given amino acid 
position is calculated by dividing the total number of different amino acids at 
that position by the frequency of the most common amino acid at that position. 
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2.3.2 Design of a hydrophilic ADRB2 surface  
To design the water-soluble surface of ADRB2 based on the 
54 phospholipid-exposed positions, we used a subset to the amino acids 
EKRQAVLF to replace the wild-type amino acids (colored in blue in 
Fig. 2.3). The hydrophilic and charged amino acids (EKRQ) were used to 
confer a water-soluble character to the receptor. The hydrophobic amino 
acids (AVLF) were used to preserve of the wild-type-like hydrophobic 
character of a given position in case a hydrophilic amino acid would not 
be tolerated at this position. 
Not all 54 positions were randomized to the same extent. Rather we 
defined an optimal subset of replacement amino acids for each 
randomized position, taking into consideration the wild-type amino acid 
at a given position. For example, Leu is the wild-type amino acid at 
position 45 in TM1 of ADRB2, and we incorporated the amino acid 
subset EKRQAL at this position, which includes the wild-type Leu. 
Designing a restricted subset of amino acids at each position has the 
advantage of strongly reducing the theoretical complexity of the library. 
Figure 2.3 shows the design of the 54 positions in the seven TM helices 
(blue boxes) 
 
Figure 2.3: Design of the seven TM helices. The 54 amino acid positions that 
are randomized for increasing the water-soluble surface of ADRB2 (blue) and 
the 16 positions that are randomized or replaced to increase the overall #-
helical content of a helix (yellow) are shown. The amino acid types that are 
inserted at a given position in the library are shown to the right of each helix. 
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The redesign of each TM helix of ADRB2 resulted in seven highly 
randomized helices; each of them showed a theoretical complexity of up 
to 106 different sequence variants. We wondered how likely the 
redesigned helices would adopt #-helical secondary structure in aqueous 
solution. We therefore took an abstract look at each helix by analyzing 
their characteristics as independently folding peptide chains – decoupled 
from the structural context of the 7TM fold. To this end, we employed a 
computational model – AGADIR – that predicts the #-helix formation for 
peptides in aqueous solution with high accuracy11,12. The AGADIR model 
provides a quantitative representation of experimentally derived statistical 
parameters, such as intrinsic secondary structure propensities and position 
dependence of the 20 amino acids, as well as physical parameters, such as 
electrostatic or side-chain side-chain interactions, that defines the folding 
of #-helices.  
We applied the AGADIR algorithm to the each of the seven helical 
peptide ensembles to predict their tendency of forming #-helical 
secondary structure. The algorithm computed the helical content (at the 
single residue level) for every possible peptide sequence that would 
theoretically exist in a helix sub-library (Fig. 2.3). The results for the 
peptide sequences corresponding to the seven wild-type TM helices of 
ADRB2, which show a very strong hydrophobic character, showed a very 
low #-helical secondary structure content of 1-2% (averaged over the 
entire peptide). The analysis of the redesigned helices, however, showed 
two interesting results. First, the redesigned helices were very different in 
their #-helical content. In the libraries of TM1 and TM4 we found many 
sequence variants that showed more than 25% helical content on average. 
In contrast, most of the sequences in the libraries of TM2, TM3, TM5, 
TM6 and TM7 showed less than 5% #-helical content. This difference is 
most probably due to the fact that TM1 and TM4 represent rather 
regularly shaped helices in the ADRB2 crystal structure, while TM2, 
TM5, TM6 and TM7 are distorted by proline-induced kinks. The low #-
helical content of TM3, however, most probably relates to its strong 
hydrophobic character, which it retains in the redesigned version of the 
receptor because TM3 is largely buried in the receptor core. A second 
finding from the analysis by AGADIR was that replacing some of the 
wild-type Gly, Ser or Val residues by Ala or Leu strongly increased the 
#-helical content of TM1, TM4 and TM5. For example, replacing Gly37, 
Val39 and Ser41 by Ala or Leu in TM1 led to a large increase in #-
helical content as illustrated in Figure 2.4. Gly50, however, which is 
predicted to break off TM1, could not be replaced, because it is highly 
conserved in the GPCR superfamily. 
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Figure 2.4: Visualization of a calculation by AGADIR on seven designed 
sequences of TM1. The percentage helical content for each amino acid position 
is shown on top, the corresponding amino acid peptides of TM1 at the bottom. 
Replacing Gly, Val or Ser residues by Ala or Leu (orange boxes) leads to a 
strong increase of the #-helical content of TM1. 
The results obtained by the AGADIR calculations suggested that the 
helical content of the library could be increased by small modifications to 
the sequence. We therefore decided to include 16 positions in the 
redesign of the receptor (colored in yellow in Fig. 2.3) to improve the 
overall helical content of the library (in addition to the 54 positions, 
which were randomized with a subset of the amino acids EKRQAVLF to 
confer water-solubility to the receptor). Many of the modifications 
suggested by the AGADIR calculations were in good agreement with 
data obtained from multiple sequence alignments of the adrenergic 
receptor family, where the suggested amino acids also occurred at 
homologous positions of closely related adrenergic receptors. 
As a last modification in the library, we decided to mutate five Cys 
residues in the C-terminus (at the positions 327, 341, 354, 405, and 433) 
to Ala or Ser in order to limit the formation of non-specific disulfide 
bonds during protein expression. The Cys replacements were shown to be 
accommodated in the ADRB2 model structure without interfering with 
receptor function. The final redesign of the seven TM helices is 
summarized in Figure 2.3. 
Chapter 2 33 
2.3.3 Synthesis of DNA encoding the combinatorial ADRB2 
library  
The full-length cDNA of the human ADRB2 consists of 1320 nucleotide 
base pairs that encode 440 amino acids; the library design demands a 
randomization or modification of 70 amino acid positions (54 + 16). The 
final combinatorial gene library therefore consists of seven highly 
randomized sequence segments (the TM helices), which are connected by 
six wild-type-like sequence segments (the intracellular and extracellular 
loops and the N- and C-termini). The synthesis of this complex library on 
the nucleotide level represents a difficult genetic engineering problem. 
We  decided to incorporate the randomized positions into the cDNA by a 
complete de novo resynthesis of the entire receptor cDNA. The cloning 
strategy is based on dissecting the 1320 base pairs into 12 building 
blocks; each block is synthesized individually and the 12 blocks are then 
assembled to form the full-length library (assembly scheme in Fig. 2.5). 
 
Figure 2.5: Schematic representation of the assembly strategy of the gene 
library for ADRB2 by 12 building blocks. The amino acid sequence of ADRB2 
and the randomized positions are indicated on top of the 12 blocks. The full-
length library was assembled as follows: First, the DNA for the 12 building 
blocks was synthesized (gree, brown and blue bars). The blocks for the highly 
randomized helices (green bars) were synthesized by restriction and ligation of 
four DNA fragments per block (see Fig. 2.6). The building blocks for the 
moderately randomized helices (brown bars) were synthesized by assembly 
PCR using overlapping oligonucleotides. The building blocks that encode only 
wt DNA (dark blue bars), were synthesized by a commercial vendor. The 12 
building blocks were then ligated to form six modules for reading-frame 
selection (grey bars). The six modules can be ligated to form the full-length 
library of ADRB2. 
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The synthesis of the highly randomized building blocks that encode the 
TM helices 1, 4, 5, 6 and 7 (green bars in Fig. 2.5) presented the biggest 
conceptual and experimental challenge. These blocks are composed of 
about 20 to 30 triplet codons (60 to 90 base pairs) of which every second 
to third codon is highly randomized (encoding a subset of the amino acids 
EKRQAVLF). Unfortunately, it is not possible to assemble such helical 
building blocks (80 to 110 nucleotides long, including the terminal 
restriction sites) from one single oligonucleotide without facing serious 
problems regarding the oligonucleotide quality (mainly problems of 
oligonucleotide shortening). We therefore decided to synthesize each 
randomized helical building block from four shorter fragments, which 
were encoded on four randomized oligonucleotides (Fig. 2.6). The 
middle part of each oligonucleotide encodes five to six amino acids 
positions of the helix (colored in grey in Fig. 2.6). It is flanked on both 
sides by a constant stretch of nucleotides that encodes a recognition site 
for a type IIs restriction endonucleases (colored in green in Fig. 2.6). This 
oligonucleotide design allows the precise enzymatic cleavage of each of 
the four DNA fragments on both sides (fragments a, b, c and d in 
Fig. 2.6). By this cleavage, the flanking parts of the DNA fragment are 
removed and specific 5’-overhangs are formed on the middle part that 
encodes a fragment of the helix. The four restricted fragments are then 
connected by enzymatic ligation to form a complete helical building 
block. The quality of the synthesized helical building blocks was verified 
by the sequencing of 19 randomly picked sequences of TM1 and TM5. 
More than 50% of the sequences showed the expected sequence pattern 
and reading frame.  
The remaining seven building blocks (dark blue bars and brown bars in 
Fig. 2.5) account for about 70% of the receptor sequence and they encode 
either few randomized positions (as in the building blocks TM2 and 
TM3) or no randomized positions at all (as in IL1, EL2, IL3 and the N- 
and C-termini). To obtain the DNA for these building blocks, we 
employed a simpler synthesis strategy than for the highly randomized 
building blocks for the TM helices. The building blocks for TM2 and 
TM3 were constructed by assembly PCR using overlapping 
oligonucleotides. We verified the quality of the assembled DNA by the 
sequencing of eight randomly picked sequences and found that more than 
50% of the sequences showed the expected sequence pattern and reading 
frame. The remaining five building blocks, which encode wild-type DNA 
only (dark blue bars in Fig. 2.5), were ordered in a double-stranded DNA 
format from a commercial vendor. 
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Figure 2.6: Synthesis at the DNA level of a building block encoding a highly 
randomized helix. One building block (e.g. TM6 shown here) is synthesized 
from four double-stranded DNA fragments denoted  a,b,c and d. The two 
fragments a and b are shown at the DNA level on the top left, the two other 
fragments c and d are shown schematically on the top right. Each fragment 
encodes in its middle part a quarter of the nucleotide base pairs of a designed 
TM helix (colored in grey). Restriction enzyme recognition sites for BpiI and 
BsaI (colored in green) flank the middle part. Note that the recognition sites for 
BpiI and BsaI are distant from their cleavage sites (continuous line in the DNA 
sequence). The amino acid sequences are indicated above the genetic 
sequences (X indicates a randomized amino acid position). The synthesis of a 
complete building block works as follows. First, the four fragments are cleaved 
by either BpiI or BsaI. Fragment a is then ligated to fragment b; fragment c to 
d. In the second step, the two resulting fragments are again cleaved by either 
BpiI or BsaI. They are then ligated to form the full-length helical building 
block composed of the grey coding regions a, b, c and d. The resulting 
building block can then be ligated to its neighboring building blocks to form 
the full-length library (schematically shown in Fig. 2.5).  
As mentioned above, the sequence analysis of the highly randomized 
helical building blocks had revealed that about 50% of the sequences 
were not in the correct reading frame due to insertions or deletions in the 
nucleotide sequence. While this error rate may be considered as relatively 
small on the level of a single building block, it would strongly increase 
when the full-length library is assembled from the individual building 
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blocks. Based on the 50% error rate, the fraction of correct full-length 
sequences in the final library was estimated to be only about 1% (0.56 = 
0.012). This represented a 100-fold reduction in the sequence space that 
we intended to sample in the subsequent selection by ribosome display. 
In order to improve the quality of the library before starting the selection 
by ribosome display we decided to perform an experiment that aims at 
removing the faulty out-of frame sequences from the library. 
To perform the reading-frame selections we implemented a method 
published by Lutz and coworkers13. The procedure demands that bacteria 
are transformed with the library of interest. Unfortunately, due to 
experimental limitations in this transformation step, only about 107 
individual variants can be sampled by the reading frame selection. The 
intended size of our full-length ADRB2 library, however, was 1012 to 1013 
sequence variants (this upper limit of the sequence space that can be 
sampled is imposed by the ribosome display method). The reading-frame 
selection, therefore, had to be performed before the 12 building blocks 
were ligated to form the full-length library. To this end, the 12 building 
blocks were assembled to form six modules for reading-frame selection 
(colored in grey in Fig. 2.5) – none of them exceeded a theoretical library 
size of 107. 
The reading frame selection, however, turned out to be very 
problematic. The control experiments failed to prove the concept. At this 
stage of the project, I teamed up with my coworker Hilmar Ebersbach to 
solve these problems. Ebersbach had worked on a similar project as mine. 
Within four months he had optimized the experimental parameters of the 
system and had established a robust reading-frame selection procedure.  
In the meantime, however, I got engaged in experiments with my 
coworker Casim Sarkar. I found his studies on the directed evolution of 
GPCRs highly fascinating and he had made very good progress in the 
past couple of months. Since his time in our laboratory was coming to an 
end, it was agreed that I would continue his experiments. Eventually, 
these experiments kept me busy for the following years and they led to 
the studies presented in the Chapters 4 and 5 of this thesis. My attention 
had gradually shifted away from the project on the water-soluble ADRB2 
described in this chapter. At present, the project is temporarily stopped at 
the final stages of synthesizing the full-length library. 
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2.4 Materials and methods 
Sequence analysis and homology modeling. Multiple sequence 
alignments (MSAs) were calculated with ClustalW using standard 
parameters. The MSAs were manually adjusted if necessary. Homology 
modeling was performed with Insight II software on a SGI Octane 
Workstation. The homology model of the human !2 adrenergic receptor 
was build based on the crystal structure of bovine rhodopsin (PDB code 
1f88). The model was restricted to the seven TM helices. The amino acid 
sequences of the seven TM helices of ADRB2 were aligned to the 
homologous regions of rhodopsin. The initial model was built by 
assigning the backbone coordinates of rhodopsin to the homologous 
positions of ADRB2. Then the side chains were assigned. The 
orientations of the side chains were optimized to remove steric clashes 
and to saturate hydrogen-bonding contacts by sampling the backbone-
dependent rotamer library implemented in Insight II. Major steric clashes 
around TM2 and in the interface between TM3 and TM4 were removed 
by minor adjustments in TM2 and TM4. The solvent accessibly surface 
area for each amino acid in the model was calculated by rolling a probe 
(radius = 1.4 Å) over the receptor surface. 
AGADIR. The AGADIR algorithm was run on peptides representing the 
designed TM helices. The following parameters were used: N-terminal = 
acetylation, C-terminal = amidation, temperature = 298 K, pH = 7.4, ionic 
strength = 0.2 M NaCl. 
Synthesis of the gene library encoding water-soluble ADRB2 analogs. 
Unless stated otherwise, all experiments were performed as described14. 
DNA amplified by PCR was always purified by agarose gel 
electrophoresis. Oligonucleotides encoding the highly randomized 
positions in the gene library were synthesized by Metabion (Germany) by 
incorporating mixed trinucleotides15 as building blocks (Glen Research, 
USA). The following mixtures of trinucleotides were used to encode a 
subset of the amino acids EKRQAVLF. 
Table 2.1: Composition of the five trinucleotide mixtures encoding a 
subset of the amino acids EKRQAVLF (% values). 
 Mix 1 Mix 2 Mix 3 Mix 5 Mix 6 
E 34 34 34 32 10 
K 17 17 17 16 30 
R 17 17 17 16 30 
Q 14 9 9 8 10 
A 18 13 13 12 20 
F    16  
L  10    
V   10   
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All other oligonucleotides were from Microsynth (Switzerland). All 
PCRs were done with Phusion polymerase (Finnzymes). The restriction 
endonucleases BpiI and BsaI were from NEB (USA) and Fermentas 
(Canada). 
The DNA of the highly randomized building blocks  TM1, TM4, TM5, 
TM6 and TM7 (green bars in Fig. 2.5) was synthesized by four 
oligonucleotides; their sequences are shown below. The randomized 
positions in the oligonucleotide sequence are indicated by boldface font 
and the numbers (1, 2, 3, 5 and 6) indicate the trinucleotide mixtures 
incorporated at a given position (for their amino acid composition, see 
Table 1). If degenerated genetic code – in addition to the trinucleotide 
mixtures – was used for randomization, it is indicated by the standard 
symbols also highlighted in boldface. For some fragments it was 
necessary to encode the randomized positions on more than one 
oligonucleotide (e.g. tm4_a). For clarity, the nucleotide segment 
encoding a given helix fragment is separated from the constant flanking 
segments by a space character. The experimental procedure for 
synthesizing an entire building block encoding a randomized helix is 
described in Figure 2.6. 
Oligonucleotides for building block TM1: 
tm1_a 5’-CGCAGCAGGAAGACGG GGTGGHAGSCATGGCG1CTGATG CGAGACCAGCAGAACGG-3’ 
tm1_b 5’-CGCAGCAGGAAGACGG GATG11ATTGTG2GCGA CGAGACCAGCAGAACGG-3’ 
tm1_c 5’-CGCAGCAGGAAGACGG GCGATT31GGCAAT CGAGACCAGCAGAACGG-3’ 
tm1_d 5’-CGCAGCAGGAAGACGG CAAT1CTGGTGATTAMGGCGA CGAGACCAGCAGAACGG-3’ 
 
Oligonucleotides for building block TM4: 
tm4_a1 5’-CGCAGCAGGAAGACGG GACCRAAAACRAAGCGC CGAGACCAGCAGAACGG-3’ 
tm4_a2 5’-CGCAGCAGGAAGACGG GACCRAAAACCTGGCGC CGAGACCAGCAGAACGG-3’  
tm4_a3 5’-CGCAGCAGGAAGACGG GACCRAACAGRAAGCGC CGAGACCAGCAGAACGG-3’  
tm4_a4 5’-CGCAGCAGGAAGACGG GACCRAACAGCTGGCGC CGAGACCAGCAGAACGG-3’  
tm4_b 5’-CGCAGCAGGAAGACGG GCGCRGGMAGTGATT66GTGT CGAGACCAGCAGAACGG-3’ 
tm4_c 5’-CGCAGCAGGAAGACGG GTGTGG1GTGKCGGCG CGAGACCAGCAGAACGG-3’ 
tm4_d 5’-CGCAGCAGGAAGACGG GGCG1ACCAGC5CTGC CGAGACCAGCAGAACGG-3’ 
 
Oligonucleotides for building block TM5: 
tm5_a 5’-CGCAGCAGGAAGACGG CCAGGMATACGCG3GCGTCGGCG CGAGACCAGCAGAACGG-3’ 
tm5_b 5’-CGCAGCAGGAAGACGG GGCG13GCGTTTTAT2CCGC CGAGACCAGCAGAACGG-3’ 
tm5_c 5’-CGCAGCAGGAAGACGG CCGCTG13ATG31GTGT CGAGACCAGCAGAACGG-3’ 
tm5_d1 5’-CGCAGCAGGAAGACGG GTGTATGCGCGCGTGTTTCAAG CGAGACCAGCAGAACGG-3’ 
tm5_d2 5’-CGCAGCAGGAAGACGG GTGTATGCGCGCGTGCAGCAAG CGAGACCAGCAGAACGG-3’ 
 
Oligonucleotides for building block TM6: 
tm6_aT 5’-CGCAGCAGGAAGACGG GCTGGMAACCCTGGCG3ATTATG CGAGACCAGCAGAACGG-3’ 
tm6_aV 5’-CGCAGCAGGAAGACGG GCTGGMAGTGCTGGCG3ATTATG CGAGACCAGCAGAACGG-3’ 
tm6_b 5’-CGCAGCAGGAAGACGG TATG1AYCTTTAMG2TGCTGG CGAGACCAGCAGAACGG-3’ 
tm6_c 5’-CGCAGCAGGAAGACGG CTGGCKTCCGTTCTTT1GTGAAC CGAGACCAGCAGAACGG-3’ 
tm6_d 5’-CGCAGCAGGAAGACGG GAAC33CATGTGAWAMAAGATA CGAGACCAGCAGAACGG-3’ 
 
Oligonucleotides for building block TM7: 
tm7_a 5’-CGCAGCAGGAAGACGG GATAACCTGATTCSCAAAGAA CGAGACCAGCAGAACGG-3’ 
tm7_b 5’-CGCAGCAGGAAGACGG AGAAGHATATATT2CTGAACT CGAGACCAGCAGAACGG-3’ 
tm7_c 5’-CGCAGCAGGAAGACGG AACTGG1GGCTAT1AACA CGAGACCAGCAGAACGG-3’ 
tm7_d1 5’-CGCAGCAGGAAGACGG AACAGCGCGTTTAACCCGCWGATTT CGAGACCAGCAGAACGG-3’ 
tm7_d2 5’-CGCAGCAGGAAGACGG AACAGCGCGTTTAACCCGGMGATTT CGAGACCAGCAGAACGG-3’ 
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The DNA for the two building blocks for TM2 and TM3 (brown bars 
in Fig. 2.5) were synthesized by assembly PCR using the following 
oligonucleotides: 
 
Oligonucleotides for building block TM2: 
tm2_1 5’-CGCAGCAGGAAGACGG TCTG1ATGGGC2GCCGTTGTGCCATTCGGTG-3’ 
tm2_3a 5’-ATGAAGATGTGGACGTTCGGCAACSAGTGGTGTGAG5TGGA CGAGACCAGCAGAACGG-3’ 
tm2_3b 5’-ATGAAGATGTGGACGTTCGGCAACTTCTGGTGTGAG5TGGA CGAGACCAGCAGAACGG-3’ 
 
Oligonucleotides for building block TM3: 
tm3_1 5’-CGCAGCAGGAAGACGG TGGACCKCGATCGACGTCTTATGCGTCACGGCCAGCATTGAAACCC-3’ 
tm3_2 5’-CGGGCTCGTAATCGCCWGATAGCGGTCTDCCGCAATGACACCACGGGTTTCAATGCTGGCC-3’ 
tm3_3 5’-GGCGATTACGAGCCCGTTCAAATACCAAAGCTTACTGACC CGAGACCAGCAGAACGG-3’ 
 
The following primers were used to generate double-stranded DNA 
from the above oligonucleotides by PCR. They anneal to the constant part 
of each randomized oligonucleotide. 
 
Bpi_for 5’-CGCAGCAGGAAGACGG-3’ 
Bsa_rev 5’-CCGTTCTGCTGGTCTCG -3’ 
 
The double-stranded DNA for the building blocks N-ter, IL1, EL2, IL3 
and C-ter (blue bars in Fig. 2.5) was synthesized by Geneart (Germany) 
and provided in a plasmid format. These building blocks were amplified 
by PCR from the plasmid and ligated to other building blocks according 
to the scheme in Figure 2.5. 
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2.5 Conclusions and future directions 
The conversion of the !2 adrenergic receptor into a water-soluble 
receptor analog presents a very challenging protein-engineering problem. 
In this chapter, I have described a strategy towards solving this problem. 
It is based on the principles of directed evolution, namely mutagenesis 
and selection. This chapter describes the redesign of the phospholipid-
contacting surface of ADRB2 and the implementation of the redesign by 
the synthesis of a combinatorial library on the DNA level. Although the 
final proof that a GPCR can be converted into a water-soluble analog has 
not yet been demonstrated here, the results presented in this study provide 
a strong experimental framework towards this goal. 
The future directions in this project comprise two main steps. First, in 
order to complete the synthesis of the combinatorial library, the six 
reading-frame selection modules have to undergo reading-frame selection 
based on the experimental conditions proposed by Hilmar Ebersbach. The 
six modules can then be assembled to form a high-quality full-length 
library. Second, the library should be selected for ligand binding 
competence by ribosome display in order to isolate ADRB2 receptor 
analogs that adopt the 7TM fold in aqueous solution. 
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Figure S1: Specific binding of 0.1 nM [3H]-NT to cells expressing NTR1 in the specific 
buffers. ‘‘Standard’’ is the normal binding assay buffer, defined in the Methods section, 
and contains 1 mM EDTA, which renders the outer membrane fully permeable. A 5x buffer 
formulation comprises 250 mM Tris, 750 mM chloride salt, pH 7.4. Note that the 
extracellular ligand concentration used here is approximately the Kd value. 
 
 
Figure S2: Total, nonspecific, and specific binding of 50 nM [3H]-NT to cells expressing 
NTR1 in the specific buffers. ‘‘Standard’’ is the normal binding assay buffer, defined in the 
Methods section, and contains 1 mM EDTA, which renders the outer membrane fully 
permeable. A 5x! buffer formulation comprises 250 mM Tris, 750 mM chloride salt, 
pH 7.4. 
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Figure S3: Influence of buffer concentration (and composition) on specific binding of 
50 nM [3H]-NT to cells expressing NTR1. Note that Tris (abbreviated ‘‘T’’) is critical for 
efficient permeabilization of the outer membrane, as evidenced by the sample with 5x KCl 
only. 
 
Figure S4: Influence of buffer concentration and composition on enrichment ratios in a 
specified gate in FACS. Scatter plots show green fluorescence on the x-axis and forward 
scatter on the y-axis. The same gate was used in all eight samples shown. In comparison to 
the other samples, the 5x Tris-KCl buffer appeared to alter cell morphology, as detected by 
shifted forward scatter. Cell viability was determined by dispensing an aliquot of recovered 
cells from FACS onto ampicillin-containing agar plates and comparing the number of 
viable colonies to the expected number of cells in that volume. 
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Figure S5: Flowchart for selections of NTR1 variants with increased expression level or 
altered ligand selectivity. 
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Figure S6: Radioligand binding analysis of 96 clones isolated from selections for 
maximum receptor expression level. The y-axis represents receptor expression level 
relative to wild-type NTR1 expression level. The 48 clones in the top plot were chosen 
from the StEP library; the 48 in the bottom from the epPCR library. Purple bars represent 
clones with expression levels at least fourfold that of NTR1; blue bars at least fivefold; and 
red bars at least sevenfold. D03 from 4EP03 MAX is the clone with the highest expression 
level in this experiment (10-fold that of NTR1). 
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Figure S7: Radioligand binding analysis of 96 clones isolated from selections for altered 
ligand selectivity. The y-axis represents receptor expression level relative to WT NTR1 
expression level. The 48 clones in the top plot were chosen from the StEP library; the 48 in 
the bottom from the epPCR library. Purple bars represent clones with expression levels at 
least fourfold that of NTR1 and blue bars at least fivefold. G10 from 4EP03 SR is the clone 
with the highest expression level in this experiment (fivefold that of NTR1). 
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Figure S8: Flow cytometric analysis of D03 compared to WT NTR1. The mean 
fluorescence signal obtained for D03 in the presence of saturating BODIPY-NT alone is an 
order of magnitude greater than that of NTR1. However, this signal can be fully competed 
by addition of either excess NT or excess SR 48692. 
 
 
 
Figure S9: Flow cytometric analysis of G10 compared to WT NTR1. The mean 
fluorescence signal obtained for G10 in the presence of saturating BODIPY-NT alone is 
approximately fivefold that of NTR1. This fluorescence signal can be fully competed by 
addition of excess NT; however, addition of excess SR 48692 does not achieve full 
inhibition. 
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Figure S10: Snake plot of NTR1 highlighting the silent (gray) and nonsilent (black) 
mutations in D03. The location of the key selectivity mutation in G10 (F358S) is also 
highlighted on this plot, although this mutation does not exist in D03. 
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Figure S11: Variation in cytosolic calcium levels in individual HEK293T cells in 
response to 1 nM NT. Each trace represents a single cell and is characterized as plateau 
(bold green), transient (bold blue), or oscillatory (bold red). 
 
 
 
Figure S12: Ca2++signaling in HEK293T cells expressing NTR1fl or D03fl (fl, full 
length, i.e., no N-terminal truncation). A comparison with Fig. 3 in the main text 
suggests that the N-terminal truncation has minimal effect on the nature of signal 
transduction through these receptors. Oscillatory, plateau, and transient responses 
are illustrated in Fig. S11 and defined in the SI Text. 
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Figure S13: Whole-cell Western blot of NTR1, D03, and D03-L167R expressed in E. coli. 
Each lane was loaded with 5 µl of cell suspension (adjusted to OD600 = 25). The C-terminal 
His10 tag was detected with a primary mouse anti-His4 antibody and a secondary anti-
mouse IgG alkaline phosphatase conjugate. The arrow indicates the recombinant fusion 
protein (MBP-GPCR-TrxA-His10) with the expected molecular mass of 100.2 kDa. 
 
 
Figure S14: NTR1, D03, and D03-L167R were analyzed by Western blot. In each lane, 
20 µg of total membrane protein was loaded. The GPCR precursor form was detected with 
anti-prepro-!-factor antiserum [primary; courtesy of Randy Schekman (University of 
California, Berkeley)] and alkaline phosphatase conjugated goat anti-rabbit-IgG 
(secondary). The arrow on the right of the blot denotes the size corresponding to this 
precursor form. The negative control (ctrl) lacks a GPCR insert. 
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Figure S15: Position of the mutation C7054G in the secondary structure of RNA II555 of 
ColE1-harboring plasmid pRG. The structural model shows that C7054G is positioned near 
the mutation that confers high levels of plasmid replication to pUC derived plasmids and 
close to the region which is complementary to the 5’ tail region of RNA I. [Reproduced 
with permission from ref. 1 (Copyright 1986, Elsevier).] 
 
Figure S16: Effect of the mutation C7054G (located in the origin of replication of the 
plasmid pRG) on receptor expression and plasmid production levels in E. coli. Receptor 
expression increases for D03 but not for NTR1, when expression is driven from the 
mutated plasmid pRG_C7054G. C7054G leads to a twofold increase in cellular plasmid 
content independent of the receptor gene cloned into the vector. All ratios were calculated 
based on data that had been normalized for OD600. 
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Figure S17: Gel filtration profiles of NTR1 (Left; loaded 200 µg of functional receptor at 
6.7 µM) and D03 (Right; loaded 310 µg of functional receptor at 10.4 µM). The main 
protein peak elutes at Ve = 11.9 ml and consists of functional receptor (see Fig. S18). 
 
 
 
Figure S18:  Overlay of a D03 gel filtration profile (solid black line) and the 
corresponding functional receptor content of collected sample fractions as assessed by [3H]-
NT binding assays (open gray columns). The dominant peak (Ve = 11.9 ml) contains 
functional receptor. 
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Figure S19: Analysis of individual mutations in D03, which contains 14 nucleotide 
substitutions compared to NTR1. The first 15 columns in the graph represent NTR1 (solid 
white), 5 silent substitutions (vertical hash pattern), and 9 single-site mutants of WT that 
each introduces the evolved amino acid at that position in D03 (diagonal pattern). Likewise, 
the last 15 columns in the graph represent D03 (black bar), 5 silent substitutions (vertical 
hash pattern), and 9 single-site mutants of this GPCR that each reintroduces the 
corresponding WT amino acid (diagonal pattern). All constructs were expressed in the 
original expression vector lacking the backbone mutation (C7054G). Results represent 
three independent expression series. 
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5.1 Abstract 
We recently developed a novel method for the directed evolution of integral 
membrane proteins in the inner membrane of Escherichia coli1. Using as the 
first example the neurotensin receptor NTR1, a mammalian G-protein coupled 
receptor (GPCR), we arrived at a sequence with a 10-fold increase in 
functional expression that still retains the biochemical properties of wild type. 
This mutant also shows enhanced heterologous expression in eukaryotes (12-
fold in Pichia pastoris and 3-fold in HEK293T cells). Most importantly, the 
evolved mutant also shows greater stability when detergent solubilized and 
purified, indicating that the biophysical properties of the protein had been 
under the pressure of selection. To demonstrate that the approach can be 
applied generally, we have now studied three additional human GPCRs. 
Unmodified wild-type receptor cDNA was subjected to this novel membrane 
protein engineering method. Functional expression could be successively 
increased with each round of evolution for all three GPCRs. Interestingly, for 
one receptor – a peptide binding GPCR which to date has resisted expression 
in E. coli – various variants could be quickly evolved to mg/l functional 
expression levels. In the present study we also developed a new stability 
screen in a 96-well assay format to quickly screen the pools of evolved 
receptor variants for candidates showing increased thermal stability in 
detergent solubilized from. The improvements are based on cumulative small 
changes in the receptor sequence. They are achieved by a combinatorial 
approach that does not require the input of rational design principles. Existing 
roadblocks in structural and biophysical studies of these important targets can 
now be removed by providing sufficient quantities of correctly folded and 
stable receptor protein. 
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5.2 Introduction 
G-protein coupled receptors (GPCRs) represent the largest superfamily of 
cell surface receptors in the living world. They respond to an enormous 
diversity of extracellular signals, including neurotransmitters, hormones, ions 
and photons. When an incoming signal molecule or photon interacts with the 
GPCR, the receptor undergoes large conformational rearrangements whereby 
the signal is directly transmitted to intracellular G-proteins2. When activated 
by a GPCR, the G-proteins switch from a GDP to a GTP bound state, and the 
subsequent dissociation into their !- and "#-subunits can activate a variety of 
different intracellular signaling pathways.  
Because of the enormous diversity in transmitted signals, GPCR signaling 
is involved in nearly every physiological process, and deregulated signaling 
readily leads to pathologic conditions. Of the nearly 800 different GPCRs 
identified in the human genome3, about 300 GPCRs are considered 
pharmaceutically relevant (excluding the receptors for odor or taste). 
Presently, about 30 of these are targeted by about 25% of all known drugs in 
clinical use. The remaining majority of GPCRs are considered potential high-
value drug targets. Due to the central biomedical role of GPCRs in human 
physiology and pathology GPCRs have attracted a lot of research in academia 
and industry.  
Among these research efforts, the crystallographic determination of a three-
dimensional receptor structure represents a central methodology for 
investigating GPCR function at atomic resolution. Despite tremendous 
research efforts made in GPCR crystallography, structure determination 
remains enormously difficult and to date the structures of only five different 
GPCRs could be solved4-8. Moreover, this set is somewhat redundant, because 
the  "1 and "2 adrenergic receptors are very closely related and the visual cone 
pigment rhodopsin was solved from two different species. Yet, the structures 
provide detailed structural insights into receptor function and ligand binding 
contacts at atomic resolution and they were successfully used for structure 
based ligand discovery9. Analysis of the five receptor structures reveals many 
conserved structural features as well as many important structural differences 
that may account for the enormous functional diversity observed in GPCR 
signaling. It is very likely that the important and often unique structural 
differences cannot be extrapolated between different members of the GPCR 
superfamily. It will therefore be necessary to solve the structure of most 
GPCRs individually to fully explore their pharmacological potential. 
The experimental procedure of obtaining a crystal structure typically 
involves three steps: the protein has to be functionally expressed, solubilized 
in detergent micelles, and crystallized. However, for most integral membrane 
proteins, especially for those of animal origin such as GPCRs, each of these 
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steps turns out to be very problematic. GPCR expression in native tissue is 
typically very low and it is therefore necessary to set up a robust heterologous 
overexpression system. Standard techniques for finding acceptable 
overexpression conditions include screening of expression hosts, promoters, 
fusion adducts and protein homologs. However, even if all of these expression 
parameters are optimized, most GPCRs may not yield sufficient material for 
crystallographic studies. When acceptable expression conditions are found, the 
problem of extracting the GPCR out of the lipid bilayer by detergents limits 
the process towards crystallization, because GPCRs are intrinsically unstable 
proteins and quickly lose their native fold when solubilized. 
In a previous study we addressed these roadblocks by analyzing the 
capacity of the receptor sequence itself as an experimental parameter for 
overcoming the problems of low receptor expression and stability1. To this 
end we developed an evolutionary selection method consisting of random 
mutagenesis and selection by fluorescence-activated cell sorting (FACS) 
based on the versatile expression host Escherichia coli. By applying this 
evolutionary selection method to the model GPCR neurotensin receptor NTR1 
we identified mutations which strongly improve functional surface expression 
and stability, while wild-type biochemical function was largely retained1. In 
the present study we further validated this selection method on three 
additional human GPCRs of the rhodopsin family.  
More specifically, we wanted to characterize two important technical 
aspects of the method in order to assess its potential for being generally 
applicable to the members of the GPCR superfamily. The first aspect relates to 
the possibility of increasing functional expression independent of the wild-
type heterologous expression level, by evolving even very weakly expressed 
GPCRs. The second aspect relates to the identification of the most 
thermostable receptor mutants in a pool of well-expressed mutants by a newly 
developed stability screen in a 96-well assay format. We investigated the 
performance of the new stability screen to see how readily stable receptors can 
be identified among the well-expressed ones. By characterizing mutations that 
increase expression and those that increase stability and those that increase 
both, important information about the structural basis of those effects can be 
learned. 
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5.3 Materials and methods 
Library construction. The three human GPCRs to be evolved were the 
tachykinin receptor TACR1, the !1a adrenergic receptor ADRA1a, and the !1b 
adrenergic receptor ADRA1b. The wt cDNA encoding these receptors was 
obtained from the Missouri S&T cDNA Resource Center (www.cdna.org). 
The full-length cDNA (except the ATG start codon) was cloned into a 
derivative of the expression vector pRG/III-hs-MBP (kindly provided by R. 
Grisshammer, National Institutes of Health) via the BamHI and Cfr9I 
restriction sites. This vector derivative encodes a N-terminal fusion of MBP to 
the receptor and a C-terminal fusion of TrxA. To create genetic diversity, the 
DNA encoding the GPCR (excluding the fusion adducts) was amplified by 
error-prone PCR using the GeneMorph II Random Mutagenesis Kit 
(Stratagene). Ten ng of template DNA was amplified for 30 cycles of PCR. 
The randomized PCR product was further amplified by PCR using Phusion 
polymerase (Finnzyme) to obtain sufficient amounts of DNA for library size 
ligation into the expression vector pRG. Escherichia coli strain DH5!-E 
(Invitrogen) was used for library cloning and expression. Cells were 
transformed by electroporation. The final library size was 107 to 108 
transformed clones. Sequencing of single clones of the naïve libraries showed 
3-4 nucleotide substitutions per kilobase of DNA for the TACR1 and 
ADRA1a libraries and 2-3 substitutions for ADRA1b libraries. The sequenced 
clones showed a homogeneous distribution of mutations, including equal 
amounts of transitions and transversions, which were equally distributed on 
the four bases. Clonal amplification of the naïve library after electroporation 
took place at 37°C in 50 ml 2xYT medium containing 1% glucose. After 
electroporation the cells were grown for 1 h at 37°C, 100 µg/ml carbenicillin 
(Carb) was added, and the cells were grown for another 2-3 h. At this point the 
subpopulation of transformed cells, representing a minor fraction of the total 
biomass, were mechanically separated from the bulk cell mass of non-
transformed cells by passing the liquid culture through a 5 µm filter 
(Millipore). By this filtration step the transformed cells were recovered in the 
flow-through, while the non-transformed cells, which fail to divide under Carb 
selection but keep growing to long aggregating filaments, are retained on the 
filter. The fraction of transformed cells was centrifuged at 5,000 g for 5 min, 
resuspended in 50 ml fresh 2xYT medium containing 1% glucose and 100 
µg/ml Carb, and grown to an OD600 of 0.1. The cells were centrifuged at 5,000 
g for 5 min, resuspended in 1x Hogness modified freezing medium (HMFM) 
[36 mM K2HPO4, 13.2 mM KH2PO4, 0.4 mM MgSO4, 1.7 mM Na3-citrate, 6.8 
mM (NH4)2SO4, 4.4% (v/v) glycerol],  frozen in liquid N2 and stored at -80°C 
until further use. 
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Selection for higher expression. The basic protocol for selecting higher 
expressing receptor variants has been described in detail1. In the present study 
it was adapted as follows: A frozen library of E. coli cells was thawed and 
grown in 2xYT medium [1% glucose, 100  µg/ml Carb] at 37°C for 2 h. A 
fresh expression culture in 20 ml 2xYT medium [0.2% glucose, 100 µg/ml 
Carb] was inoculated at OD600 = 0.05, grown at 37°C to an OD600 of 0.5 and 
induced with 0.3 mM isopropyl-!-D-thiogalactopyranoside (IPTG). 
Expression took place at 20°C for 18 to 24 h. For sorting the libraries by 
FACS, the cells were diluted into ligand binding buffer at 2$108 cells/ml. For 
cells expressing the ADRA1a or ADRA1b libraries the ligand binding buffer 
was TKCl [50 mM Tris-HCl, pH 7.4, 100 mM KCl], for TACR1 it was 
5xPBS-K [50 mM K2HPO4, 9 mM KH2PO4, 0.7 M KCl, pH 7.4, (note that all 
sodium salts were replaced by potassium salts in this buffer)] supplemented 
with protease inhibitors (Complete Protease Inhibitors EDTA-free, Roche). 
ADRA1 libraries were labeled with 200 nM prazosin-BODIPY-FL 
(Invitrogen) for 1 to 2 h on ice. Non-specific binding was determined by the 
addition of 10 µM unlabeled prazosin (Tocris Bioscience). TACR1 libraries 
were labeled with 300 nM Substance P Oregon Green (Invitrogen) for 2 to 3 h 
on ice. Non-specific binding was determined by the addition of 10 µM 
unlabeled Substance P (Tocris Bioscience). The cells were washed by 
centrifugation at 10,000 g for 90 seconds and resuspension in the same 
volume of TKCl. Sorting was done on a FACSAria II (BD Biosciences) at 
20,000-30,000 events/sec in yield mode (for sorting naïve libraries) or purity 
mode (for subsequent sorting rounds). The most fluorescent 0.5 to 1.5% of the 
cells in the population (107 to 108 cells) were sorted directly into 2xYT (1% 
glucose, 100 µg/ml Carb) for regrowth and further selection. The most 
fluorescent cells were enriched by sorting the libraries for 3 to 6 rounds by 
FACS. 
Radioligand binding assay on whole cells. Saturating radioactive ligand 
binding on whole cells was used to measure the functional surface expression 
level. Twenty µl of expression culture were added to 160 µl ligand binding 
buffer in a 96-well polyethylene plate. Ligand binding buffer for ADRA1 
clones was 50 mM Tris-HCl, 0.1% (w/v) BSA, 1 mM EDTA, 40 µg/ml 
bacitracin, pH 7.4 containing 10 nM [3H]-prazosin (Perkin-Elmer). Non-
specific binding was determinded by the addition of 10 µM unlabeled 
prazosin. Ligand binding buffer for TACR1 clones was 5xPBS-K 
supplemented with 0.1% (w/v) BSA, 40 µg/ml bacitracin and Complete 
Protease Inhibitors containing 10 nM [3H]-Substance P (Perkin-Elmer). Non-
specific binding was determinded by the addition of 10 µM unlabeled 
Substance P. After incubation for 2.5 to 3 h at 4°C the bound ligand was 
separated from the unbound by fast vacuum filtration on 96-well filtration 
plates with glass-fiber filters (MAFBNOB, Millipore) and the filters were 
Chapter 5 81 
washed with 1 ml ice cold TKCl. The filters were transferred to liquid 
scintillation vials containing 5 ml Optiphase HiSafe 2 scintillation cocktail 
(Perkin-Elmer), incubated for 24 h, and scintillation was counted on 
Betamatic II liquid scintillation counter (Kontron). To derive the amount of 
receptors/cell we assumed a cell density of 109 cells/ml per 1 unit of OD600. 
For determining equilibrium binding affinities, a dilution series of radioligand 
was used (0.1–15 nM). 
Screening of thermal stability in a 96-well assay format. A new method 
for screening the stability of solubilized receptors in a 96-well assay format 
was developed. It consists of four steps. First, the receptor is expressed and 
biotinylated in vivo. Second, the receptor is solubilized and partially purified 
by immobilization on streptavidin-coated paramagnetic beads. Third, the 
receptor is exposed to stability screening conditions that induce receptor 
unfolding (e.g. heat, detergent, buffer). Fourth, the amount of residual folded 
receptor is determined by a ligand binding assay (LBA) after exposing the 
receptor to the screening conditions. The detailed protocol is as follows: 
Biotinylated receptor was expressed using a derivative of the pRG vector that 
contains a C-terminal AviTag (GLNDIFEAQKIEWHE, biotinylation on K) 
instead of a deca-His tag. Under standard expression conditions (as described 
above) more than 60% of the receptors become biotinylated in vivo without 
the external supply of components of the E. coli biotinylation machinery (i.e. 
the addition of extra free biotin in the expression medium or co-expression of 
the E. coli biotin ligase BirA. Notably, the omission of extra biotin is very 
advantageous because free biotin strongly competes with biotinylated 
receptors for binding to streptavidin during receptor immobilization.). After 
expession, the biotinylated receptor was solubilized and partially purified by 
immobilization on straptavidin coated paramagnetic beads as follows: In a 
2 ml microfuge tube, a cell pellet corresponding to a 2 ml expression culture 
was washed once with TKCl and then solubilized in 200 µl solubilization 
buffer containing 50 mM Tris-HCl, pH 7.4, 200 mM NaCl, 30% (v/v) 
glycerol, 1 mM EDTA, Complete protease inhibitors, detergents ((dodecyl-"-
D-maltopyranoside (DDM), 1% (w/v); 3-[(3-cholamidopropyl)-
dimethylammonio]-1-propane sulfonate (CHAPS), 0.5% (w/v); cholesteryl 
hemisuccinate (CHS), 0.1 % (w/v); from Anatrace). Solubilization took place 
at 4°C for 2 h with gentle agitation. During the last 30 minutes of 
solubilization 40 µg/ml deoxyribonuclease I (Roche) and 10 mM MgCl2 were 
added. Solubilized samples were centrifuged at 20,000 g for 20 min to remove 
cell debris. The supernatant was mixed with 10 µl of Dynabeads MyOne 
Streptavidin T1 beads (Invitrogen) in a 96-well polyethylene plate and 
receptor immobilization took place for 2 h at 4°C with gentle agitation. The 
samples were transferred to a 96-well PCR plate (Bioplastics) and the beads 
were captured by a magnetic capturing device MPC9000 (Dynal). The beads 
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were washed twice with 150 µl stability assay buffer [SAB, 50 mM Tris-HCl, 
100 mM NaCl, 30% (v/v) glycerol, 1 mM EDTA, Complete Protease 
Inhibitors, 0.01% (w/v) DDM, 0.5% (w/v) CHAPS, 0.1% (w/v) CHS] and 
resuspended in a final volume of 120 µl SAB. Thermal stability was measured 
by exposing one aliquot of immobilized receptor to a specific temperature in a 
thermocycler (Biometra) for 20 min, a second aliquot was kept on ice. After 
cooling the heated aliquot on ice all samples were assayed for their content of 
folded receptor by a ligand binding assay. The immobilized receptor was 
incubated for 1.5 h on ice with 100 µl ligand binding buffer (LBB) [50 mM 
Tris-HCl, pH 7.4, 15% (v/v) glycerol, 1 mM EDTA, Complete Protease 
Inhibitors, 0.01% (w/v) DDM, 0.5% (w/v) CHAPS, 0.1% (w/v) CHS] 
containing 10 nM radioligand. The bound ligand was separated from the 
unbound by magnetic capturing of the beads, removing the supernatant, 
washing the beads once with 150 µl LBB and resuspending the beads in a 
final volume of 20 µl LBB. The beads were centrifuged at 2,000 g for 2 min 
and resuspended by sonication for 10 sec in a water bath. Scintillation was 
counted in 200 µl OptiPhase Supermix cocktail (Perkin-Elmer) on a liquid 
scintillation counter (1450 Microbeta Plus, Perkin-Elmer). The non-specific 
binding signal was less than 10% of the total signal. The stability index (SI) 
for a receptor is defined as the ratio between the residual binding signal of the 
heated receptor sample and the initial binding signal of the sample kept on ice. 
Molecular Modeling of the evolved mutations. The crystal structure of 
the "2 adrenergic receptor (PDB code 2rh1) was used to analyze the evolved 
mutations in a structural context. Pymol (DeLano Scientific) was used for 
molecular modeling and visualization. 
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5.4 Results 
5.4.1 Setup of the selection system for increasing expression 
and stability 
To characterize the performance of our selection method for evolving both 
increased functional expression and receptor stability of GPCRs, we chose 
three different human GPCRs of the rhodopsin family. These receptors show 
very different functional wild-type expression levels: tachykinin receptor 
TACR1 (%30-80 receptors/cell), !1a adrenergic receptor ADRA1a (%350 
receptors/cell) and !1b adrenergic receptor ADRA1b (%2000 receptors/cell). 
These particular receptors were primarily chosen because they had high 
affinity fluorescent ligands commercially available. TACR1 is a peptide 
binding receptor and it binds to the eleven amino acid long peptide 
Substance P, which acts as an endogenous high-affinity agonist for TACR1. 
For these selections, Substance P was used as an Oregon Green derivative 
(SP-OG; Fig. 5.1). ADRA1a and ADRA1b both belong to the amine binding 
family of GPCRs and both receptors bind to the small molecule antagonist 
prazosin with high affinity. For these selections, prazosin was used as a 
BODIPY-FL derivative (prazosin-BFL; Fig. 5.1). 
 
 
Figure 5.1: Overview of the fluorescent ligands used for the selections by FACS. 
 
For the selections, we used the highly specific ligand binding fluorescence 
signal as an indicator for functionally expressed receptor inserted in the inner 
plasma membrane of E. coli1. In order to bind to the receptors located in the 
inner membrane, the fluorescent ligands must be able to partition across the 
outer membrane (OM) of E. coli. A suitable binding buffer must therefore be 
formulated such that the OM becomes permeable for the ligand molecules 
Chapter 5 84 
without compromising cell viability. Furthermore, the binding buffer should 
not contain any components that inhibit ligand binding to the receptor. For 
TACR1 maximal specific ligand binding of SP-OG was observed in a high-
salt buffer containing 5xPBS. The sodium in PBS was substituted by 
potassium to avoid the inhibitory effect of sodium ions on SP-OG binding. For 
ADRA1a and ADRA1b maximal specific ligand binding of prazosin-BFL was 
observed in a buffer containing 50 mM Tris-HCl and 100 mM KCl (TKCl). 
 
5.4.2 Selection of receptor variants showing increased 
expression 
The functional expression level of the evolving receptor libraries increased 
with each round of mutagenesis and selection as evidenced by an increase in 
mean specific fluorescence intensity (MFI) (Fig. 5.2). The evolution of 
TACR1 started from a wt receptor that is expressed very weakly as indicated 
by the histograms of total and non-specific MFI that are almost overlapping 
for wt TACR1 (Fig. 5.2). After four rounds of evolution (ep4 pool, “ep” refers 
to “error prone PCR”, the number “4” refers to four rounds of evolution; one 
round of evolution consists of one error prone PCR and four to six rounds of 
sorting by FACS) the specific MFI of the selected TACR1 library pool was 
approximately five times higher than that of the wt receptor. Similarly, the 
evolution of ADRA1a started from a relatively weakly expressed wt receptor 
(Fig. 5.2). After four rounds of evolution (ep4 pool) the specific MFI of the 
selected ADRA1a library was 2.5 times higher than that of the wt receptor. In 
contrast to the low wt expression levels of TACR1 and ADRA1a, the wt 
ADRA1b receptor was expressed relatively well, i.e. approximately five times 
better than its close homolog ADRA1a. After two rounds of evolution of 
ADRA1b, the selected library (ep2 pool) reached a specific MFI two times 
higher than that of the wt receptor. ADRA1b was not evolved beyond the ep2 
pool. 
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Figure 5.2: Evolution of the expression signal for the three receptors TACR1, 
ADRA1a, and ADRA1b. The fluorescence distribution is shown for cells expressing 
the wt receptors (blue histograms) and for pools of evolved cells expressing a 
collection of mutant receptors (red histograms) after two and four rounds of 
evolution (ep2 pool and ep4 pool respectively). One round of evolution consists of 
one error prone PCR followed by four to six rounds of sorting by FACS. ADRA1b 
was evolved for two rounds only (ep2). The expression signal, given as the specific 
mean fluorescence intensity (MFIspec), is obtained by subtracting the background 
MFI (transparent histograms) from the total MFI (colored histograms) of cells 
labeled with fluorescent ligand. The transparent histograms are obtained by 
competing the fluorescent ligand with an excess of unlabeled ligand. 
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To quantitatively assess the increase in expression of single evolved 
receptor variants within the evolved pools, we performed radioligand binding 
assays on whole cells of randomly picked single clones. 
TACR1: The wt cDNA of TACR1 is very weakly expressed in E coli, at a 
level of 30-80 receptors/cell. In total, we applied four rounds of evolution to 
TACR1 (four error prone PCRs, each one followed by four to six rounds of 
sorting by FACS). After two rounds of evolution, we isolated single receptor 
variants that expressed up to 1200 receptors/cell (Fig. 5.3a). Two additional 
rounds of evolution augmented the expression level further and the best 
receptor variants expressed approximately 2000 receptors/cell, which 
represents a 25-fold increase in expression compared to wt TACR1 
(Fig. 5.3a). 
ADRA1a: The evolution of ADRA1a started from a wt cDNA that was 
expressed at about 350 receptors/cell. We evolved the ADRA1a receptor for 
4 rounds (four error prone PCRs, each one followed by four to six rounds of 
sorting by FACS). After two rounds of evolution we found that the best 
receptor variants expressed about 10-fold better than wt ADRA1a (Fig. 5.3b). 
After two additional rounds of evolution, expression increased further and the 
best clones now expressed more than 6000 receptors/cell, which is about 17-
fold better than wt ADRA1a (Fig. 5.3b). 
ADRA1b is a close homolog of ADRA1a, which showed a relatively high 
wild-type expression level of 2000 receptors/cell to begin with. To our 
knowledge, this represents the highest functional expression level in E. coli 
for any wt GPCR. We included ADRA1b in our set of receptors to be evolved 
because we wanted to investigate if the expression of a relatively well-
expressed GPCR may be further augmented. After two rounds of evolution we 
isolated clones that expressed 1.5 to 2-fold better than wt ADRA1b 
(Fig. 5.3c). This relatively low increase in expression of ADRA1b compared 
to the increase observed for the other evolved receptors is very likely related 
to the problems we encountered in preparing the mutant libraries for 
ADRA1b. Due to the low amplification efficiency in the error-prone PCR 
step, the ADRA1b cDNA was randomized very inefficiently. Even after two 
rounds of randomization, the mutational load of the naïve library was very low 
(data not shown). To further evolve ADRA1b expression in future studies, it 
will be necessary to optimize the conditions for error-prone PCR procedure 
for this particular cDNA. 
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Figure 5.3: Increased functional expression level of evolved receptor variants of 
TACR1, ADRA1a and ADRA1b after two and four rounds of evolution. One round 
of evolution consists of one error prone PCR followed by four to six rounds of 
sorting by FACS. The expression level of single clones was measured by 
radioligand binding assays on whole cells expressing the evolved receptor variants 
(grey bars) and the corresponding wt receptors (orange bars). (a) Single evolved 
clones of TACR1 isolated after two rounds (ep2) and four rounds (ep4) of evolution. 
(b) Single evolved clones of ADRA1a isolated after two rounds (ep2) and 4 rounds 
(ep4) of evolution. (c) Single evolved clones of ADRA1b isolated after two rounds 
for evolution (ep2). ADRA1b was evolved for two rounds only. The error bars 
indicate SD of duplicate measurements of a representative experiment. 
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5.4.3 Identifying receptor variants with increased thermal 
stability 
Establishing high expression levels of a correctly folded and membrane-
inserted GPCR is the first critical step in the process of producing sufficient 
amounts of functional protein for biophysical and structural studies. The 
second equally important step towards this goal consists of extracting the 
intact receptor from the lipid bilayer by the help of detergents and maintaining 
the functional receptor fold in detergent micelles. The parameter that 
determines the success of this second step most decisively is receptor stability. 
We were therefore interested to determine how readily we could identify 
receptor variants with increased stability within the evolved pools of higher 
expressing clones. 
The thermal stability of individual receptor variants was thus determined 
after detergent solubilization and partial purification. For this purpose, one 
receptor sample was exposed to a fixed elevated denaturation temperature 
(defined individually for each of the three receptors) for a fixed period of time 
(20 minutes), a second sample was kept on ice. Both of the samples were then 
assayed for their content of folded receptor by a radioligand binding assay 
(LBA). We define the stability index (SI) for each receptor variant as the ratio 
between the residual binding signal of the heated sample and the initial 
binding signal of the sample kept on ice expressed as a percentage. The 
denaturation temperature was defined as the temperature where the wt 
receptor would retain approximately 50% of the initial binding signal after 
heating at this temperature. We found considerable differences in the thermal 
stabilities of the three wt receptors and we therefore screened the 
corresponding evolved receptor variants as follows: wt ADRA1a was the most 
stable wt receptor and it retained approximately 55% binding signal after 
20 minutes at 40°C. wt ADRA1b, although 5 times better expressed than its 
close homolog ADRA1a, was less stable; it retained 20% binding signal after 
20 minutes at 36°C. For wt TACR1 we could not determine thermal stability 
because it was not possible to measure sufficient specific binding signal after 
receptor solubilization. Instead of wt TACR1, which is too unstable, we 
therefore decided to use as a reference point the evolved receptor variant T1-
C0, which we had isolated in the ep2 pool. We chose this particular clone, 
because it is well expressed and it deviates from the wt TACR1 sequence by 
only 4 amino acid substitutions. Clone T1-C0 retained 30% binding signal 
after heating it for 20 minutes at 31°C.  
Because we wanted to perform the stability screen on as many receptor 
variants as possible, we had to revise the ligand binding assay (LBA), which is 
the core step of the conventional method for stability assessment. In the 
conventional method, each sample has to be processed by a small size 
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exclusion spin column to separate bound from unbound ligand and assess the 
ligand binding signal, since solubilized receptor cannot be bound to filters. 
This spin-column step cannot be performed in a 96-well assay format and 
therefore strongly limits the assay throughput. The key feature of our new 
method is the immobilization of biotinylated receptor on streptavidin coated 
paramagnetic beads. By immobilizing the receptor, all essential experimental 
steps of the stability assay – purification, heat treatment and LBA – can be 
performed with small receptor amounts and in a highly parallelized format. 
Immobilized receptor can easily be separated from detergent-solubilized 
lysates of whole cells by magnetic force, which yields highly concentrated and 
purified receptor preparations. Most importantly, magnetic capturing also 
allows for a convenient separation of bound from unbound ligand in the LBA, 
which avoids the handling of size exclusion spin columns. All essential steps 
can therefore be performed in a 96-well assay format.  
We initially screened 100 to 200 evolved receptor variants for each of the 
three receptors by applying the new stability screening method. After the 
initial screen the measurement was repeated with a subset of receptors to 
confirm the results from the initial screen. 
TACR1: We screened receptor variants of the ep4 pool at 31°C and found a 
broad distribution of stability indices (Fig. 5.4a). As mentioned above, it is not 
possible to compare these data to the stability of wt TACR1, and we compared 
them instead to an alternative reference point, namely the evolved clone T1-
C0. We found that most evolved receptors of the ep4 pool were more stable 
than T1-C0. Notably, the most stable receptor we isolated (T1-E11) showed a 
stability index of 91% compared to 31% for T1-C0. To analyze how receptor 
stability relates to the expression level, we plotted the stability data as a 
function of receptor expression in Figure 5.4a. We found that, although the 
data are only very loosely correlated, there are many clones that are highly 
expressed and more stable. 
ADRA1a: We initially screened 120 single clones of the ep4 pool. 
However, we did not obtain satisfactory results for this pool, because about 
half of the sequences showed stop codons in their C-termini, which prevented 
receptor immobilization on streptavidin-coated magnetic beads via the C-
terminal biotin. Interestingly, this subset of receptors showing shortened C-
termini (and therefore lacking the C-terminal fusion adduct TrxA-Avi-tag) 
displayed higher expression levels than the full-length receptors, which 
explains their enrichment in the ep4 pool. Because of the reduced number of 
full-length receptors observed in the ep4 pool, we decided to return to the ep2 
pool, where the evolved receptors did not show C-terminal shortening. By 
screening the ADRA1a ep2 pool at 40°C, we found a broad distribution of 
stability indices, ranging from 34% to 96% (SI of wt ADRA1a was 56%) 
(Fig. 5.4b). The most stable evolved receptor variants showed almost no 
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reduction in ligand binding after the heat treatment (SI of 96%). Plotting the 
stability data as a function of expression in Figure 5.4b shows that many of 
the better-expressed receptor variants are also more stable than wt ADRA1a. 
The correlation between the two variables, however, is very loose. Overall, the 
results on ADRA1a show that the biophysical properties of a weakly 
expressed and relatively stable receptor can further be improved by applying 
the method of random mutagenesis and selection by FACS. 
 
Figure 5.4: Thermal stability as a function of expression level for evolved receptor 
variants of TACR1, ADRA1a and ADRA1b. To measure thermal stability, the 
receptors were purified and then heated at a fixed temperature for 20 minutes. The 
Stability Index (SI) indicates the fraction of receptors that survive the heating step as 
evidenced by their ability to bind ligand after the treatment. The thermal stabilities 
of wt receptors (!) are given as a reference point to the evolved receptor variants 
(!). (a) Stability of evolved TACR1 receptor variants of the ep4 pool. The samples 
were heated at 31°C for 20 min. Wild-type TACR1 failed to be functionally 
solubilized and its SI is set to 0%. Instead we used the evolved clone T1-C0 ("), 
which is well expressed and shows only four amino acid substitutions compared to 
wt, as an alternative reference point for stability. (b) Stability of evolved ADRA1a 
receptor variants of the ep2 pool. The samples were heated at 40°C for 20 min. (c) 
Stability of evolved ADRA1b receptor variants of the ep2 pool. The samples were 
heated at 36°C for 20 min. The data represent mean values of duplicate 
measurements from one representative experiment (SD " 10%).  
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ADRA1b: We screened 120 evolved clones of the ep2 pool. However, only 
four individual receptor variants could be immobilized on the magnetic beads 
and assayed for stability. All of them were more stable that wt ADRA1b (SI of 
50-60% and 20% respectively) (Fig. 5.4c). The majority of receptor variants, 
however, failed to be immobilized because of the same problem we had 
observed for clones in the ep2 pool of ADRA1a: the enrichment of stop 
codons in the evolved pools of both receptors, ADRA1a and ADRA1b, 
indicates a strong selection in favor of shortened C-termini. To be able to 
assess the stabilities of the C-terminally shortened receptors, we would have to 
reclone them into an expression cassette that restores the C-terminal Avi-tag 
for biotinylation.  
Despite the problems with shortened C-termini observed for ADRA1a and 
ADRA1b, we have successfully applied the new stability screen to three 
different wt receptors. For each receptor we could isolate many receptor 
variants, which showed higher functional expression levels and higher thermal 
stability compared to their wt progenitors. 
 
5.4.4 Relating evolved mutations to increased expression and 
stability 
To find possible structural and mechanistic explanations for how evolved 
amino acid mutations may influence expression and stability, we mapped 
them on the recently solved crystal structure of the "2 adrenergic receptor. 
TACR1: To gain insight into mutations that led to the strong increase in 
expression and stability in the evolution of TACR1, we sequenced single 
clones of the ep2 and the ep4 pools. After two rounds of evolution (ep2 pool) 
the most highly expressed sequences show 7 ± 2 (SD) amino acid substitutions 
per receptor, the sequences are diverse and the mutations are distributed over 
the entire cDNA (Fig. 5.5a). There are two strong consensus mutations, I204T 
and T222R, both located in TM5 (boxed in Fig. 5.5a). Because of their high 
enrichment in the ep2 pool – the best expressed mutants show at least one of 
the two mutations – they are likely to be critical for increasing receptor 
expression. The I204T mutation points into a region surrounded by TM3 and 
TM4 in the ligand binding crevice. Since it replaces the methyl group of 
Ile204 by a hydroxyl group, it is tempting to speculate that Thr204 is engaged 
in an H-bond. The second consensus mutation, T222R, is located at the 
cytoplasmic end of TM5 and points into the membrane bilayer. The increase 
in expression may arise because the positive charge of Arg222 may lead to an 
optimization of the ionic interaction energy between the receptor and the 
negatively charged phospholipid head groups of the membrane bilayer, and 
because it satisfies the positive inside rule10,11. Besides the two consensus 
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mutations, there are additional mutations in the ep2 pool, which occur at lower 
frequencies. These mutations are likely to contribute to increased expression 
levels in addition to the I204T and T222R consensus mutations. 
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Figure 5.5: Evolved amino acid mutations of receptor variants of TACR1. 
(a) Mutations of the most highly expressed receptor variants of the ep2 pool. 
(b) Mutations of randomly picked receptor variants of the ep4 pool. The receptors 
are listed based on increasing expression level. The value given in square brackets 
indicates the factor of expression increase compared to wt expression. For each 
mutation the corresponding wt amino acid and the position in the TACR1 sequence 
are indicated on top of the mutation data. Mutations occurring at a frequency of 50% 
or higher are defined as consensus mutations (boxed). The most thermostable 
receptors, which are covered in the Results section, are indicated in boldface, and 
the mutations occurring only in these clones are highlighted as grey boxes. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                     . 
 
To analyze the effect of mutations that increase the stability of TACR1, we 
sequenced clones of the ep4 pool, which had been extensively screened for 
stability. These clones cover a large range of stability indices ranging from 
10% to 91%. There are 11.6 ± 2.8 (SD) amino acid mutations per receptor on 
average, which were distributed over the entire cDNA (Fig. 5.5b). In addition 
to the two consensus mutations I204T and T222R, which were already present 
in the ep2 pool, four more mutations are strongly enriched in the ep4 pool 
(boxed in Fig. 5.5b). These mutations seem to be primarily responsible for a 
general increase in expression rather than in stability because they are not 
restricted to very stable clones. To gain insight into the strongly stabilizing 
mutations, we only analyzed mutations (colored in grey in Fig. 5.5b) that 
occur in the 7TM portion (excluding the N- and C-termini) of the most stable 
TACR1 clones. These clones are: 
T1-E11 (SI = 91%) 
T1-B02 (SI = 78%) 
T1-H04 (SI = 70%) 
T1-D10 (SI = 68%) 
 
T1-E11: Clone T1-E11 showed the highest stability index (91%) and it had 
two mutations, A146G and V211M, which did not occur in any other 
sequence. Mapping the mutations on the crystal structure of  "2 adrenergic 
receptor (ADRB2) shows that the A146G mutation is located at the 
cytoplasmic end of TM3 and that the V211M mutation is located in the middle 
of TM5. Both mutations are located on the outside faces of the helices and 
point into the solvent. Clone T1-E11 also features the K243N mutation, which 
is also present in other stable clones. K243N is located at the cytoplasmic end 
of TM6 and points towards IL2. In the absence of a detailed atomic model of 
TACR1, however, it is not evident how the three mutations may contribute to 
higher stability of TACR1. 
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T1-B02: Clone T1-B02 was the second most stable clone (SI of 78%) and it 
figured among the best expressed ones. It shows four mutations, which are 
likely to increase stability. The A93G and T124M mutations are unique to 
clone T1-B02 and the V51M and N309D mutations are shared with other 
stable clones. The T124M mutation introduces a Met residue in TM3 at the 
interface between TM3 and TM5 and the Met side chain is located near the 
helix kink introduced by the highly conserved Pro2085.50 in TM5. The bulky 
side chain of Met124 could possibly provide stabilizing hydrophobic contacts 
in the interface between TM3 and the helix kink in TM5. Interestingly, the 
T124M mutation in clone T1-B02 and the V211M mutation in the most stable 
clone T1-E11, although separated in the sequence, are adjacent in the receptor 
tertiary structure. Both Met side chains point into the same interface region 
between TM3 and TM5. This suggests that the helical interface around the 
helix kink introduced by Pro2085.50 may play a critical role in the stability of 
TACR1. Besides the T124M mutation, the other three mutations (V51M, 
A93G, and N309D) in clone T1-B02 that may be responsible of increased 
receptor stability are located in different regions of the receptor. It is not 
obvious how those may increase stability. 
The two very stable TACR1 clones mentioned above are succeeded in 
stability by the two clones T1-H04 and T1-D10, both showing stability indices 
around 70%. The unique mutations in these clones are I191T in EL2 and 
G166A at the extracellular end of TM4. 
ADRA1a. To analyze the evolved mutations of the ADRA1a selection, we 
sequenced 48 single clones of the ep2 pool (these clones correspond to the 
data points presented in Figure 5.4b). There were 24 different sequences 
among the 48 sequenced clones. These sequences are diverse, the mean 
deviation from the wt sequence is 6.8 ± 2.2 (SD) amino acids per receptor and 
the mutations are distributed over the entire cDNA (Fig. 5.6). 
Figure 5.6 
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There are several mutations that occur with high frequency in the evolved 
ADRA1a sequences. The most prominent of these consensus mutations is 
found at position 14 in the N-terminus of the receptor. In 96% (23/24) of the 
evolved sequences the wt Cys residue at position 14 was mutated to either of 
the amino acids Tyr, Phe, Ser or Arg (Fig. 5.6). We analyzed the effect of two 
different single point mutants at position Cys14 (C14S and C14R) and found 
that the expression for either of the two mutants was five times higher than for 
wt ADRA1a (data not shown). This strong effect is most likely related to the 
elimination of Cys14, which would prevent Cys14 from engaging in the 
formation of non-specific intramolecular or intermolecular disulfide bonds in 
the oxidizing periplasm of E. coli. The most probable intramolecular partners 
for such non-specific bonding would be either Cys99 in TM3 or Cys176 in 
EL2, because they are close to Cys14 in the receptor structure. Interestingly, it 
is these two Cys residues that form the putative conserved disulfide bond in 
the native receptor fold. For practically all GPCRs, including ADRA1a, this 
disulfide is needed for a functional receptor. During receptor expression, the 
formation of a non-specific disulfide bond involving Cys14 may even be 
favored over the formation of the specific one, because Cys14 and Cys99 are 
translocated into the periplasm before Cys176. Interestingly, the closely 
related receptor subtype ADRA1b shows a Ser residue instead of Cys at the 
corresponding position. This small difference in the sequence may provide a 
simple explanation for the 5-fold difference in expression between the two 
!1 adrenergic receptor subtypes.  
The second strong consensus mutation found in the ep2 pool of ADRA1a is 
F312L/I located in TM7 and pointing into the ligand binding crevice. The 
occurrence of F312L/I was associated with two different phenotypic effects. 
First, all clones that contained this mutation showed a strong increase in 
stability compared to wt ADRA1a. Second, these clones showed an 
unexpectedly low binding signal for the antagonist radioligand [3H]-prazosin, 
which we used for measuring the functional expression level. Both of these 
effects can be exemplified in the double mutant clone A1a-29, which shows 
the C14R and F312L mutations. On the one hand, clone A1a-29 was more 
stable than wt ADRA1a because of the F312L mutation (SI of 83%). On the 
other hand, A1a-29 showed only a two-fold increase in ligand binding signal 
instead of a five-fold increase, which we would have expected based on the 
C14R mutation. While this reduction in ligand binding signal by F312L could 
be explained by lower receptor expression, it is more likely caused by a 
reduction in binding affinity for [3H]-prazosin. This interpretation is supported 
by the observation that Phe312 plays a critical role in the high affinity binding 
of  !1 adrenergic receptor antagonists12. Indeed, we observed that the F312L 
mutation at the corresponding position in the closely related receptor 
ADRA1b (the F334L mutation) increased the equilibrium dissociation 
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constant (Kd) for [3H]-prazosin from 0.3 nM to 2.1 nM (Fig. 5.7). A similar 
drop in affinity in ADRA1a, which is expected as a result of the F312L 
mutation, would prevent full ligand occupancy of expressed receptors in the 
radioligand binding assays, which we performed at a concentration of 10 nM 
[3H]-prazosin. The effective expression level of evolved ADRA1a clones 
showing the F312L mutation in Figure 5.6 (and of ADRA1b clones showing 
the the F334L mutation in Fig. 5.11) may therefore be underestimated by 
roughly 25%. This observation also shows that our selection method does not 
primarily select for higher ligand affinity, but indeed for the desired properties 
of expression level and stability. 
 
Figure 5.7: Affinity determined with [3H]-prazosin for evolved receptor A1b-C10 
compared to wt ADRA1b. The equation y = ymax · x / (Kd + x) was used for a non-
linear fit of the equilibrium binding data. 
 
Besides the two strong consensus mutations mentioned above (C14X and 
F312L), two additional consensus mutations (N322K and N318H) occurred in 
the ep2 pool of ADRA1a, which are associated with the best expressing 
clones. Molecular modeling using the ADRB2 crystal structure showed that 
both of these mutant residues are located in TM7 and that they are likely to 
interfere with the highly interconnected hydrogen bonding network consisting 
of the conserved residues Asn511.50, Asp792.50, Asn3187.45, Asn3227.49, 
Tyr3267.53 and several structural water molecules (Fig. 5.8). In the model, the 
introduction of either of the mutations N322K or N318H leads to the 
elimination of native hydrogen bonds formed by the corresponding wt 
residues. However, for both mutated residues Lys322 and His318 it is possible 
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to model rotamers that allow the formation of new alternative polar contacts 
depicted in Figure 5.8. In the case of the N322K mutation, which mutates the 
Asn residue of the highly conserved NPxxY signature motif in TM7, the 
mutant Lys322 side chain may possibly form a salt bridge with the highly 
conserved wt residue Asp792.50 in TM2, which may promote a receptor 
conformation favoring higher expression 
 
Figure 5.8: Structural model of the N318H and N322K mutations in ADRA1a. 
These mutations occurred in the highest expressing clones of the ep2 pool of 
ADRA1a. The model predicts that the mutant amino acids His318 and Lys322 may 
participate in the highly interconnected hydrogen-bonding network involving highly 
conserved residues in TM1, TM2 and TM7 and structural water molecules. The 
putative wt hydrogen bonds are indicated by yellow dots, the hydrogen bonds 
formed by the mutant residues in pink dots. The model is based on the crystal 
structure ADRB2 (PDB code 2rh1). Numbers in superscript denote the amino acid 
position according to the Ballesteros-Weinstein numbering scheme. 
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 In addition to the strong consensus mutations discussed above, we 
identified mutations in the ep2 pool of ADRA1a, which occurred only the 
clones that showed the highest thermal stability (Fig. 5.6). These clones are: 
A1a-05 (SI = 96% ± 1%) 
A1a-42 (SI = 96%) 
A1a-22 (SI = 89% ± 3.3%) 
A1a-09 (SI = 87%). 
A1a-05: Of the nine mutations in the most stable clone A1a-05, five are 
most likely responsible for the high increase in receptor stability because they 
are located in the 7TM fold. The beneficial effect of one of these mutations 
(F312L) was already mentioned above. Mapping the remaining four mutations 
on the crystal structure of ADRB2 provides a possible model for how the 
interplay of at least three of them (A93P, F98L and K309T) may lead to 
higher stability of ADRA1a. This model suggests that the Pro residue of the 
A93P mutation is introduced at a flexible region in the EL1 loop, which may 
be a critical region for receptor stability (Fig. 5.9). Pro93 is flanked by two 
highly conserved wt aromatic residues (colored in cyan in Fig. 5.9), which 
seem to participate in an extended conserved aromatic cluster around EL1. 
These flanking residues are Trp92, which forms a tight contact with the 
conserved disulphide bridge between TM3 and EL2, and Phe94, which 
contacts conserved aromatic residues in TM2.  Replacing Ala for Pro at 
position 93 would remove flexibility in EL1 and thereby stabilize the highly 
interconnected aromatic cluster around this loop. In addition to the A93P 
mutation, the two other mutations F98L and R309T are likely to be coupled to 
conformational rearrangements induced by Pro93. First, the removal of the 
bulky benzene ring by the F98L mutation may allow room for the side chain 
of Phe94 to adopt a new rotamer, which would lead to stabilizing contacts 
with TM3. Second, the removal of Lys309 by the K309T mutation in TM7, 
which removes a putative ionic contact with Glu87 in TM2, suggests that 
TM2 adapts to the changes induced by Pro93, possibly by moving closer to 
TM7 and forming new contacts. Such a helix movement seems probable 
because the ionic contact constraining the TM2-TM7 helical interface is lost 
and because the movement could be facilitated by the helix kink in TM2, 
which is induced by the conserved Pro812.50. The model further suggests that 
the conformational rearrangements induced by the mutant residues Pro93, 
Phe98 and Lys309 could be coupled to the structural changes induced by the 
stability enhancing consensus mutation F312L in TM7. It is therefore likely 
that the strong increase in stability in clone A1a-05 arises because of the 
synergistic action of the all four mutations. 
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Figure 5.9: Structural model of the mutations A93P, F98L, R309T, and F312L in 
the highly stabilized clone A1a-05 of ADRA1a. The models on top show an 
extracellular view of EL1. The models in the bottom show a side view of TM2 and 
TM7. On the left side are models of the wt receptor and on the right side are models 
of the mutants (mutant residues are colored in orange). Pro93 is introduced between 
two highly conserved aromatic residues (colored in cyan), which participate in an 
extended aromatic cluster around EL1. The model is based on the crystal structure of 
ADRB2 (PDB code 2rh1). 
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A1a-42: Clone A1a-42 is another very stable ADRA1a mutant showing a 
stability index of 96%. In addition to the consensus mutation L312F, it shows 
two unique mutations in the 7TM fold, V21L and G164A. The V21L mutation 
lies in the N-terminus and it is difficult to rationalize how it may increase 
stability. G164A, however, lies at the extracellular helical end of TM4. The 
substitution of Gly for Ala could possibly remove flexibility and therefore 
stabilize the connection between TM4 and EL2.  
A1a-22: Clone A1a-22 was the third most stable clone (SI of 89%) and its 
sequence occurred at the highest frequency (7/48 sequenced clones) in the ep2 
pool of ADRA1a. It contains the unique A189S mutation in TM5, which is the 
most likely cause for the increase in stability. Interestingly, all members of the 
adrenergic receptor family but ADRA1a show Ser and not Ala at the 
homologous position in TM5. We suppose that the A189S mutation may lead 
to an increase in stability because the hydrogen-bonding properties of Ser. 
A1a-09: Finally, clone A1a-09 appears among the most stable clones (SI of 
87%) without featuring the stability enhancing consensus mutation F312L. We 
speculate that either of the unique mutations L42M or S129N may be 
responsible for the stabilizing effect. Molecular modeling shows that evolved 
Met42 in TM1 points into the lipid bilayer. The Met residue may – upon 
receptor solubilization – possibly engage in favorable hydrophobic 
interactions with the hydrophobic moieties of detergent molecules. The S129N 
mutation is located one helical turn away from the Tyr1253.51 residue of the 
highly conserved DRY motif in TM3. The molecular model in Figure 5.10 
shows that the evolved Asn129, but not the wt Ser129, may form a hydrogen 
bond with Tyr1253.51 of the DRY motif in TM3. This interaction may 
constrain conformational changes induced upon receptor activation, which 
have been proposed for the receptor region surrounding the DRY motif13,14. 
 
Figure 5.10: Structural model of the S129N mutation in clone A1a-09 of ADRA1a. 
The wt Ser129 is likely to form hydrogen bonds with the helix backbone and cannot 
contact Tyr125 of the conserved DRY motif. The mutant Asn129, however, may 
form a hydrogen bond with Tyr125. This contact may limit conformational 
flexibility in this important receptor region. The model is based on the crystal 
structure of ADRB2 (PDB code 2rh1). 
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ADRA1b. To analyze the mutations leading to increased expression and 
stability of evolved ADRA1b clones, we sequenced eight selected clones of 
the ep2 pool (Fig. 5.11). Four of them correspond to the only clones that could 
be immobilized on paramagnetic beads and assayed for stability (Fig. 5.11, 
set A). The other four sequences represent randomly picked clones from the 
large fraction of clones in the ep2 pool, which were selected for higher 
expression, but for which we could not to measure stability because they 
failed to be immobilized on beads (Fig. 5.11, set B). On average, the eight 
clones show 4 ± 2 (SD) amino acid mutations per receptor. Interestingly, all 
clones show the stabilizing F334L consensus mutation (boxed in Fig. 5.11), 
which is homologous to the F312L mutation observed for many sequences in 
the ep2 pool of ADRA1a. This Phe to Leu mutation was therefore evolved 
convergently in the two independent selections of both !1 adrenergic receptor 
subtypes. The sequencing data of ADRA1b also suggests that the removal of 
negative charges in the EL2 loop by mutating either Asp191 or Glu194 to a 
different amino acid may be responsible for an increase in the expression. 
Moreover, the removal of a positive charge at the cytoplasmic end of TM6 by 
the K291N mutation in clone A1b-F08 may be responsible for doubling the 
amount of expressed receptor. 
 
 
Figure 5.11: Evolved amino acid mutations of receptor variants of ADRA1b after 
two rounds of evolution (ep2 pool). The sequences are split in two parts. (set A) 
Full-length receptors. (set B) Receptors showing an opal stop codon in their C-
terminus. Note that the F334L consensus mutation in ADRA1b corresponds to the 
F312L consensus mutation in ADRA1a. The highlighted elements are as in 
Figure 5.5. 
 
The observation that many of the evolved ADRA1b clones failed to be 
immobilized is explained by the fact that the codon for Cys384 near the C-
terminus was mutated to an opal stop codon in these receptors. The opal stop 
codon leads to premature termination of translation and therefore prevents 
biotinylation of the C-terminal Avi-tag, which is necessary for immobilizing 
the receptor on streptavivdin-coated beads. Note that clone A1b-C02 
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(Fig. 5.11) could be immobilized despite showing a stop codon. In this case, 
however, it is not an opal but an amber stop codon, which is strongly 
suppressed in the E. coli DH5-! strain we were using. The amber suppression 
allows for the translation of a full-length receptor and therefore clone A1b-
C02 could be immobilized and assayed for stability. A more general 
implication of the high occurrence of stop codons in the evolved clones of 
both !1 adrenergic receptor subtypes is that shortening their relatively long C-
termini is beneficial for high level expression. Furthermore, the observation 
that receptors became shortened near their C-termini, but never within their 
7TM portion, may be explained by the fact that our selection method is based 
on ligand binding as a stringent selection criterion for conserving the 
structural integrity of the 7TM fold. 
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5.5 Discussion 
 
The inability to express GPCRs at high levels and to maintain their stability 
in detergent micelles restricts the process of crystallization and structure 
determination. To overcome these restrictions we have developed an 
evolutionary selection method that allows the rapid identification of mutations 
in the receptor sequence, which lead to higher functional expression and 
higher stability. In a previous study we have demonstrated the feasibility of 
the method on the model protein neurotensin receptor NTR11. In the present 
study we further validate the method by successfully applying it to three 
additional human GPCRs of the rhodopsin family. More specifically, we 
wanted to test if GPCRs could be evolved for higher expression independent 
of their wild-type expression level, and how readily we could isolated well-
expressed mutants, which also show increased biophysical stability in 
detergent solubilized form. 
5.5.1 Increasing expression and stability 
This study shows that the functional expression level of three wt GPCRs 
could be strongly increased independent of their basal heterologous wt 
expression level. The increase in expression was especially high for the 
evolved receptor variants of TACR1 and ADRA1a, which both show very low 
wt expression. For TACR1, which is hardly expressed in E. coli, we could 
improve the expression level 25-fold (from 80 to 2000 rec/cell). For the low 
expressing ADRA1a we found an 11-fold increase in expression (from 330 to 
3500 rec/cell). Even for the relatively well expressed wt ADRA1b, we isolated 
receptor variants showing a 2-fold increase in expression (from 2000 to 4000 
rec/cell). These levels would roughly correspond to 2 mg/l functional GPCR 
(excluding the fusion partners) at a cell density of OD600 = 5, and therefore 
constitute amounts clearly in the range of structural studies. 
The rapid identification of the most stable receptor variants among the well-
expressed ones was enabled by a newly developed stability screen in a 96-well 
assay format. By this screen we isolated highly stabilized and well-expressed 
clones such as T1-E11 and T1-B02 derived from TACR1 or the clones A1a-05 
and A1a-09 derived from ADRA1a. In general, we found that most receptors 
that were better expressed were also more stable, but the two variables were 
only loosely correlated. This observation is consistent with the fact that during 
the selection, mutants are primarily selected for their increased functional 
expression level rather than biophysical stability. However, the data shows 
that increased biophysical stability is an important factor for higher expression 
among several other factors, which are unrelated to receptor stability. 
Importantly, for many receptors, both properties need to be improved. 
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A receptor, which cannot be expressed, is not useful for structural studies, 
even if it is more stable than the wt receptor. Our method allows to quickly 
find stabilizing mutations, among a pool of better expressed mutants. 
5.5.2 Technical aspects of the selection method 
In addition to our two primary findings discussed above, a note on three 
further technical aspects may be of interest when discussing the performance 
of the presented method. First, the method was implemented without making a 
priori assumptions about the structure or the function of the targeted receptor. 
To initiate the selection process we simply chose wt cDNA of receptors, for 
which fluorescent ligands were commercially available. Genetic 
manipulations were restricted to the removal of internal restriction sites and 
did not change the amino acid sequence. The wt receptors were cloned into the 
expression vector including all of their potentially problematic features such 
as loops, N- and C-termini or possible protease sites. To initiate the selection 
process, it was not necessary to employ classical techniques of expression 
optimization. The results in this study were obtained by keeping all expression 
conditions constant. 
The second technical aspect addresses the concept of introducing mutations 
into the receptor for increasing expression and stability. In order to avoid the 
enrichment of highly expressed but misfolded mutants we are employing a 
selection mechanism that relies on ligand binding as a functional selection 
criterion. The ability to bind a ligand molecule represents a strong criterion for 
structural integrity because for most GPCRs the ligand binding site is 
contributed by residues from different parts of the receptor, which must be in a 
particular three-dimensional arrangement. Therefore, the helices and loops 
must be oriented in a native-like conformation to provide the functional 
contacts for ligand binding. Indeed, the evolved receptors typically retain a 
functional ligand binding site. Radioligand binding analysis showed that the 
evolved receptor variants bound their cognate ligand with high affinity. As an 
exception to this general outcome we observed that many evolved clones of 
ADRA1a and ADRA1b showed the Phe to Leu consensus mutation in TM7. 
This mutation led to a 10-fold decrease in affinity for prazosin binding to 
ADRA1b. The loss of affinity, however, coincided with a considerable gain in 
receptor stability.  
We are well aware of the fact, that selecting for mutations that preserve the 
ligand binding site does not rule out the possibility of selecting for mutations 
that affect other important functional features of a GPCR, such as functional 
coupling to G-proteins. In fact it is very probable that some stabilizing 
mutations do exert their effects by constraining conformational flexibility 
whereby the equilibrium is shifted towards a more active or more inactive 
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receptor state. In a previous study on the directed evolution of NTR1, we have 
analyzed in great detail the signaling profile of a receptor variant (D03), which 
we had evolved for higher expression and stability1. Indeed, the D03 receptor 
retained wt-like affinity for its agonist neurotensin (as we had expected based 
on the selection pressure). Its efficacy in Ca2+ signaling was still present, but it 
required a 10-100 fold higher agonist concentration than in wt NTR1, 
suggesting a higher rigidity of the evolved receptor. 
Despite the fact that stabilizing mutations may change the signaling profile 
of a mutated GPCR we believe that restraining conformational flexibility 
represents a decisive advantage for the crystallographic determination of 
GPCR structures. This was recently demonstrated by solving the crystal 
structure of the turkey "1 adrenergic receptor, which was made possible by 
introducing 6 stability enhancing mutations in the receptor6. Similarly, the 
thermal stabilization of bovine rhodopsin by an engineered disulfide bond in 
bovine rhodopsin has enabled its recombinant production for the first time, as 
reported in a recent study15. This protein could then be crystallized and its 
structure solved. Before this mutation was found, rhodopsin had to be 
extracted from the bovine retina to obtain sufficient protein for structural 
studies4. 
As a third technical aspect of the method, we want to note that the 
successful selection for higher expression and stability relies on both a strong 
functional selection criterion (such as ligand binding) as well as on the ability 
to sample a large sequence space. Sampling the largest sequence space 
possible increases the chances for isolating the few beneficial mutants among 
the majority of non-functional ones, which inevitably dominate a naïve gene 
library generated by random mutagenesis. In this study we routinely analyzed 
107 to 108 mutant clones per selection round. These numbers were achieved on 
a high speed FACS, which analyzes cellular parameters (such as receptor 
expression) individually for each clone. Our results indicate that the sequence 
space was large enough to sample several different amino acids at every given 
position in the sequence. For example, we found that Cys14 in ADRA1a, a 
residue that strongly impairs expression in wild-type, was mutated to four 
different amino acids in the evolved clones (Tyr, Phe, Ser and Arg). 
Therefore, the Cys codon in the naïve gene library must have been 
randomized at all three positions of the codon to give rise to the selected 
mutations. A further evidence for thorough sampling of the sequence space is 
the convergent evolution of the Phe to Leu consensus mutation in TM7 in two 
independent selections on the two homologous receptors ADRA1a and 
ADRA1b. Most importantly, the sampled sequence space was large enough to 
allow for the identification of very rare but highly beneficial mutations. 
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5.5.3 Relating mutations to evolved properties 
What mutations make the evolved receptors better expressed and more 
stable and what molecular mechanisms may be involved in the improvements? 
The general conclusion we draw from this study is that there exist many 
different mutation patterns for a GPCR sequence that lead to improved 
expression and stability. For example, we identified mutations that increase 
expression, but not stability, and most likely do not alter the native tertiary 
receptor structure at all. This is the case for the mutation of Cys14 in the N-
terminus of ADRA1a. Replacing Cys14 increases expression about five-fold 
without affecting stability. The simplest and most likely explanation for this 
strong effect may be that the elimination of Cys14 prevents the formation of 
non-native intramolecular disulfide bonds during co-translational receptor 
insertion into the membrane. Other mutations, such as the combination of four 
mutations in the evolved clone A1a-05 of ADRA1a, strongly increase receptor 
stability, which is the most likely explanation for the increase in expression, 
too. A detailed examination of a subset of evolved mutations we predict as the 
most relevant ones is given in the Results section. As yet, many of these 
predictions remain speculative to a certain degree and it will be necessary to 
test the mutations individually for their actual contributions. This information 
would then enable the engineering of receptor variants that would profit from 
combining the best mutations in a single sequence. 
5.5.4 Conclusions 
In recent years, the field of membrane protein engineering has advanced 
more and more. Some of the recently developed techniques aim at improving 
membrane protein expression level, for example by manually screening blots 
of random mutants16. Other techniques aim at identifying mutations that 
increase protein stability in detergent micelles. These techniques include the 
functional screening of random mutants17 or the systematic screening of 
alanine substitutions18. Yet other techniques aim at identifying functionally 
critical amino acids in GPCRs19-21. Complementary to such approaches, we 
have developed a protein engineering platform that allows the simultaneous 
identification of well-expressed and stable GPCR variants that retain their 
functional ligand binding properties. The method has now been validated on 
four different GPCR of the rhodopsin familiy. The results in this study show 
that our method represents a nearly assumption-free experimental platform 
and it should therefore be generally applicability to other members of the 
GPCR superfamily. Moreover, the analysis for the selected mutations will be 
valuable in understanding the structural contribution to stability and folding in 
GPCRs. 
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General conclusions and future perspectives 
  
The promise of future research in structural biology of GPCRs includes 
elucidating the differences between the active and inactive receptor 
conformations, the molecular interactions between receptors and ligands, 
and structures of GPCRs in complex with effector proteins such as G-
proteins or !-arrestins. Therefore, it is necessary to overcome the 
experimental roadblocks in producing sufficient amounts of soluble, 
stable and pure GPCRs. In this doctoral thesis I have worked on three 
different protein engineering strategies for removing some of the largest 
experimental roadblocks. 
The possibility of engineering a water-soluble analog of a GPCR is 
still a matter of debate and it surely demands a large portion of 
imagination to believe in its feasibility. A proof of this concept has not 
yet been demonstrated within the scope of this thesis. Nevertheless, the 
combinatorial methods of directed evolution may provide the key 
technology to reach this ambitious goal. To this end I have synthesized a 
semi-rational gene library that can be used to select for water-soluble 
GPCR analogs. The next experimental steps will focus on the 
implementation of a suitable display method (e.g. ribosome display) for 
performing the selections on the library. 
From our study on the engineering of opioid receptors by domain 
swapping I conclude that small biophysical improvements can be attained 
by this strategy. However, the improvements are in no way sufficient to 
produce crystallization-quality soluble material. Nevertheless, the 
application of this strategy to other GPCR families may be helpful to 
elucidate structure-function relationships between closely related 
homologs. 
The studies on the directed evolution of GPCRs by FACS were the 
most successful. We could show that even small changes to the amino 
acid sequence can lead to strong improvements in functional expression 
and stability of GPCRs while wild-type biochemical properties can be 
largely retained. For the rapid identification of critical amino acids we 
have developed a powerful method based on the principles of directed 
evolution. Notably, the method represents a nearly assumption-free way 
of engineering the biophysical properties of integral membrane proteins. 
Our results on four different GPCRs demonstrate that the method should 
be generally applicable to the GPCR superfamily. The method, however, 
is not limited to GPCRs. Any integral membrane protein, for which a 
specific fluorescent ligand can be synthesized, can potentially be evolved. 
If the evolved proteins are more stable because of enhanced rigidity, they 
may also be more likely of form diffraction-quality crystals for structural 
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determinations. The ability to obtain such high-resolution structures may 
help to elucidate the molecular basis for activation, inactivation, or 
pathology associated with a given receptor, and may also provide 
templates for drug design. 
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Abbreviations 
 
2xYT   double strength yeast extract trypton medium 
A2A   adenosine receptor A2A 
ADRA1a  !1a adrenergic receptor 
ADRA1b  !1a adrenergic receptor 
ADRB2  "2 adrenergic receptor 
AU   absorbance unit 
BFL   BODIPY fluorescein like 
BODIPY  Boron-dipyrromethene 
BSA   bovine serum albumin 
Carb   carbenicillin 
CB1   cannabinoid receptor type 1 
CB2   cannabinoid receptor type 2 
cDNA  complementary DNA 
CHAPS  3-[(3-cholamidopropyl)-dimethylammonio]-1-propane sulfonate 
CHS   cholesteryl hemisuccinate 
D2   dopamine receptor D2 
DDM   dodecyl- "-D-maltopyranoside  
ep   error prone 
epPCR  error prone PCR 
FACS  fluorescence-activated cell sorter 
FI   fluorescence intensity 
GFP   green fluorescent protein 
GPCR  G-protein coupled receptor 
GRAFS  glutamate rhodopsin adhesin frizzled/taste2 secretin 
H1   histamin receptor type 1 
HMFM  Hogness Modified Freezing Medium 
IMAC  immobilized metal-ion affinity chromatography 
IPTG   isopropyl- "-D-thiogalactopyranoside 
Kd   equilibrium dissociation constant 
LBA   ligand binding assay 
MBP   maltose binding protein 
MFI   mean fluorescence intensity 
MSA   multiple sequence alignment 
NCBI   National Center for Bioinformatic Information 
NT   neurotensin 
NTR1  neurotensin receptor type 1 
OD   optical density 
OM   outer membrane 
PCR   polymerase chain reaction 
PDB   Protein Data Bank 
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RMSD  root mean square deviation 
SASA  solvent accessible surface area 
SCAM  substituted-cysteine accessibility method 
SI   stability index 
SP   substance P 
SP-OG  Substance P Oregon Green 
TACR1  tachykinin receptor type 1 
TEV   tobacco etch virus 
TrxA   thioredoxin A 
wt   wild-type
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